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and Schwann cells in the peripheral nervous system (PNS) 
( Fig. 1 ). The wrapping of myelin around an axonal seg-
ment increases axonal resistance and enables clustering of 
axonal ion channels at nodes of Ranvier ( 1 ). As such, my-
elinating glial cells shape the structural and electrical 
properties of axons resulting in a 10- to 100-fold increase 
in nerve conduction velocity ( 2, 3 ) and in a great reduc-
tion of axonal energy consumption ( 4 ). 
 One of the prominent biochemical characteristics that 
distinguishes myelin from other membranes is its high 
lipid-to-protein ratio; lipids account for at least 70% of the 
dry weight of myelin membranes ( Table 1 ) , which is also 
the physical basis for its biochemical purifi cation by su-
crose gradient centrifugation ( 5 ). 
 The myelin membrane contains myelin-specifi c proteins 
(e.g., myelin basic protein, myelin-associated glycopro-
tein, and proteolipid protein), but no truly myelin-specifi c 
lipids. Nevertheless, whereas all major lipid classes are 
present in myelin as in other membranes, myelin has its 
characteristic lipid composition. The myelin membrane 
contains a high level of cholesterol of at least 26% by 
weight (or 52 mol%) ( Table 1 ) ( 6, 7 ). The importance of 
cholesterol for myelin production and maintenance has 
recently been reviewed ( 8 ). The myelin membrane is also 
substantially enriched in galactolipids (31% vs. 7% for 
liver cell plasma membranes). Two glycosphingolipids, 
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 The rapid saltatory conduction of action potentials 
along axons is crucially dependent on myelination. The 
myelin membrane is an extended and highly specialized 
plasma membrane synthesized by myelinating glial cells: 
oligodendrocytes in the central nervous system (CNS), 
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month) and is followed by myelination of the spinal cord 
and brain (CNS). The majority of myelin is assembled dur-
ing the fi rst two years of postnatal life ( 14 ), but myelina-
tion continues for 2–3 decades in the human cerebral 
white matter ( 15, 16 ). In rodents, myelination occurs pre-
dominantly during the fi rst month of life ( 17 ). The magni-
tude of the tasks that glial cells have to accomplish in a 
short period of time is easily appreciated when visualizing 
the membrane expansion taking place during myelination 
( Fig. 1 ). In rodents, it has been estimated that the myelin-
membrane surface area of one glial cell expands at a rate 
of 5–50 × 10 3   m 2 /day, compared with the surface area of 
the cell soma (i.e., the plasma membrane) of   0.3 × 10 3 
  m 2 ( 18 ). This corresponds to an estimated 6,500-fold in-
crease in membrane surface between an immature and a 
fully myelinated oligodendrocyte ( 19 ). In rodents, the ex-
pansion of the myelin membrane correlates with substan-
tial accumulation of cholesterol and lipids in both the 
developing CNS and PNS ( 17, 20–22 ). More recently, tran-
scriptional profi ling of developing peripheral nerves shed 
light on the molecular cascades involved in PNS myelin 
assembly ( 23, 24 ). It was observed that transcripts encod-
ing structural myelin proteins and enzymes involved in 
myelin lipid biosynthesis were expressed in a highly syn-
chronized and timely fashion, suggesting a strict control of 
a balanced and local production of these two key compo-
nents of myelin assembly. Relatively little is known about 
myelin lipid turnover in vivo, but studies in mice indicate 
a necessity to renew myelin lipids in adult life ( 25 ). 
 MYELIN DEFECTS IN INHERITED DISEASES 
AFFECTING LIPID METABOLISM 
 The lipid-rich composition of myelin is likely to contrib-
ute to the frequent occurrence of myelin defects in lipid 
metabolism disorders, including hypomyelination (decreased 
myelin production), dysmyelination (abnormally formed 
myelin), and demyelination (degenerative loss of myelin). 
Inherited forms of these diseases are particularly informa-
tive and provide direct insight into the underlying molecu-
the monogalactosylsphingolipids cerebroside and sul-
fatide account for 14%–26% and 2%–7% of myelin lipids, 
respectively ( 9–11 ). When compared with hepatocyte and 
erythrocyte membranes, myelin membranes also contain a 
higher proportion of saturated long-chain fatty acids ( Fig. 
2 ). Finally, the lipid content of myelin is also enriched in 
plasmalogens (etherlipids). These glycerophospholipids, 
defi ned by a vinyl ether double bond at the sn-1 position, 
account for 20% of the myelin phospholipid mass (com-
pared with 18% in the average human phospholipid mass). 
Here, 70% of the total phosphatidylethanolamine in white 
matter is plasmalogen, in contrast to only 5% in liver ( 12, 
13 ). These lipid characteristics of myelin, together with 
the presence of myelin-specifi c proteins, are likely re-
quired for myelin wrapping and/or to confer the specifi c 
biophysical properties of myelin as an electrical “insula-
tor”, as will be discussed below. 
 During development of the human nervous system, my-
elination starts in the motor roots of the PNS (fi fth fetal 
 Fig.  1. Ultrastructural comparison of the mem-
branes of a promyelinating versus a mature myelinat-
ing glial cell. Electron micrographs of normal mouse 
sciatic nerves showing (A) promyelin fi gure at postna-
tal day 0 (P0) and (B) adult myelinated fi ber (P100). 
The inner lip (also called inner mesaxon) of the my-
elinating glial cell, which turns around the axon to 
form the membranous spiral of myelin, is depicted 
with an asterisk (*). Scale bar, 0.5   m. Sciatic nerve 
isolation and electron microscopy were done as de-
scribed in ( 110 ). 
 TABLE 1. Approximate lipid composition of the myelin membrane 
Myelin Membrane a 
Liver Cell
Plasma Membrane b 
Lipid content (dry weight)  71% 34%
 Lipid class 
Cholesterol  26% 17%
Phospholipids
PE 16% 7%
PS 6% 4%
PC 12% 24%
PI 1% 4
SM 3% 20%
Glycolipids  31% 7%
Other lipids 5% 17%
 a From Norton and Poduslo 1973 ( 6 ): myelin of adult rat brain. 
Comparable lipid amounts are present in myelin of rodent peripheral 
nerve, with the exception of much higher SM levels (10–35%) ( 7 ).
 b From Dod and Gray, 1968 ( 164 ): plasma membrane of adult rat 
liver. The category ‘other lipids’ contains free fatty acids, triglycerides 
and cholesterol esters, which could be indicative for contamination by 
other membranes. Comparable lipid amounts were found by Ray et al., 
1968 ( 165 ). Bold numbers indicate percentages of lipids enriched in 
myelin, as discussed in the text.
 at Vrije Universiteit, Library, Dept. of Electronic Resources, on February 12, 2013
w
w
w
.jlr.org
D
ow
nloaded from
 
Lipids in myelinating glial cells 421
CNS defects in white matter are common, often involving 
corpus callosum absence or hypoplasia ( 36–42 ), and re-
ported to involve absence of myelin ( 42 ) and demyeli-
nation ( 43 ), but detailed analysis of myelin structure has 
not yet been described. The relative contribution of ei-
ther cholesterol depletion or 7-dehydro-cholesterol and 
8-dehydro-cholesterol accumulation in white matter ab-
normalities is currently unclear. Interestingly, dietary cho-
lesterol supplementation has become the standard therapy 
for SLOS and was reported to partially improve the neuro-
logical status and white matter lipid abnormalities in some 
patients ( 36, 44–46 ). Remarkably, PNS myelin defects are 
rarely reported for SLOS. The reason for this is currently 
unclear, but dietary lipid supplementation has also been 
reported to improve a case of SLOS-associated demyelinat-
ing polyneuropathy ( 47 ). 
 Mouse models of cholesterol disorders.  Multiple mouse 
models of SLOS recapitulate morphological and biochem-
ical aspects of the neuropathology of SLOS patients 
( 48–50 ). Although ventricular dilatation and partial agen-
esis of corpus callosum was observed in one of these mod-
els ( 50 ), the status of myelination was so far not analyzed 
in DHCR7 mutant animals. The importance of local cho-
lesterol biosynthesis in myelinating glial cells was, however, 
addressed by conditional inactivation of squalene synthase 
(SQS; gene symbol  fdft1 ) specifi cally in oligodendrocytes 
and Schwann cells of fdft fl ox/fl ox /cnp1 +/cre mice ( 51, 52 ) in 
which expression of cre recombinase (cre) was under con-
trol of the 2’:3 ′ -cyclic nucleotide 3 ′ -phosphodiesterase 
(cnp) promoter. In the CNS, SQS inactivation led to sub-
stantial hypomyelination and reduced motor performance 
in 20-day-old SQS conditional mutants. The discrepancy 
lar mechanisms. These involve defects in metabolism of all 
myelin enriched lipids: cholesterol, glycosphingolipid, 
and long-chain fatty acids ( Table 2 ). In several of these 
disorders the defects are caused by lipotoxicity, a result of 
the accumulation of various metabolic precursors involved 
in lipid biosynthesis to levels that are toxic to the myelin-
ating glial cells or at least interfere with normal myelin 
membrane structure [reviewed in ( 26–28 )]. Here, we will 
particularly discuss the disorders in which myelin defects 
are more likely caused by a primary defect in myelinating 
glia that causes reduced levels of myelin-enriched lipids, 
and are therefore more informative as to the contribution 
of these lipids to the synthesis and function of myelin un-
der normal and pathological conditions (see section ‘Why 
are myelinating glial cells particularly vulnerable to lipid 
metabolism disorders?’). 
 Cholesterol disorders 
 At least three different cholesterol-related disorders 
cause defects in myelin ( Table 2 ). Of these, Cerebrotendi-
nous xanthomatosis (CTX) and Tangier disease (TD) lead 
to accumulation of 7  -hydroxy-4-cholesten-3-one and cho-
lestanol (in CTX) and cholesterolesters (in TD), which 
are likely to underlie the myelin pathology [( 29–32 ),  Fig. 
3 ] . Myelin defects due to reduced cholesterol levels are 
possibly found in Smith-Lemli-Opitz syndrome (SLOS), 
which is caused by mutations in the gene encoding sterol 
delta-7-reductase (DHCR7), the enzyme catalyzing the last 
step of cholesterol biosynthesis. This results in the eleva-
tion of the cholesterol precursors 7-dehydro-cholesterol 
and 8-dehydro-cholesterol and in cholesterol defi ciency in 
all tissues ( 33–35 ). Patients with SLOS have multiple mal-
formations, cognitive impairment, and behavioral defi cits. 
 Fig.  2. Fatty acid composition of myelin compared with other membranes. Depicted is the amount of fatty 
acid in mol percentage of total amount of fatty acids. Bold numbered and gray numbered lipids depict, re-
spectively, strongly higher or lower levels of these fatty acids in myelin compared with hepatocytes or eryth-
rocyte membranes. Myelin membrane of mouse sciatic nerve were isolated as described in ( 110, 163 ). Mouse 
erythrocyte membranes and hepatocyte phospholipids were isolated and analyzed according to ( 110, 163 ). 
It should be noted that under the isolation conditions used, amide bonds in sphingolipids are relatively stable. 
Hence, the very long-chain fatty acids found in myelin are not refl ecting the high level of galactosphingolip-
ids in myelin, but are more likely to result from a particular fatty acyl composition of the glycerophospho-
lipids (phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, and phosphatidylserine). In 
addition, with the detection method used, the bar representing 18:1 fatty acids does not include 18:1 alcohol 
of plasmalogens, which nevertheless was previously detected to be very low in PNS myelin in mouse ( 110 ). 
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between the robust hypomyelination observed in SQS 
mouse mutants and the mild myelin defects observed in 
human SLOS is unclear, but may be related to the low 
amounts of cholesterol that are still produced in some 
forms of SLOS ( 33 ) and/or to the position of the defects 
leading to disruption of the cholesterol biosynthesis path-
way, which is more upstream in SQS mouse mutants. 
Whereas the amount of myelin in SQS conditional mu-
tants was decreased, its ultrastructure, lipid, and protein 
composition were not affected, suggesting a tight control 
mechanism matching the amount of myelin proteins pro-
duced by glial cells to the available cholesterol. Interest-
ingly, both hypomyelination and motor defi cits improved 
over time. These observations suggest that cell autono-
mous synthesis of cholesterol in oligodendrocytes is cru-
cial for normal onset and progression of myelination. 
Cholesterol biosynthesis-defi cient oligodendrocytes are, 
however, able to take up some cholesterol from their sur-
rounding for limited myelin formation ( 51 ). The exact 
mechanism of this horizontal cholesterol transfer remains 
to be clarifi ed. In the PNS, the inactivation of cholesterol 
biosynthesis in Schwann cells also led to substantial hypo-
myelination as detected by morphometric analysis of sciatic 
nerves from fdft fl ox/fl ox /cnp1 +/cre animals. Similar to oligo-
dendrocytes, also Schwann cells are able to take up extra-
cellular cholesterol because many axons in peripheral 
nerves from fdft fl ox/fl ox /cnp1 +/cre animals are ensheathed 
 Fig.  3. Human inherited and mouse experimental defects in the 
cholesterol biosynthesis pathway that cause myelin disorders. Solid 
line arrows depict a direct link between two steps, dashed line ar-
rows imply intermediate steps that are not shown. Dark gray ovals 
show the positions of human disease genes; light gray oval shows 
the position of mutated genes in experimental mouse models. 
Sqs, squalene synthase; DHCR7, sterol delta-7-reductase; SLOS, 
Smith-Lemli-Opitz syndrome; CYP27A1, sterol 27-hydroxylase; 
CTX, Cerebrotendinous xanthomatosis; ABC1, ATP-binding cas-
sette transporter A1; TD, Tangier disease. 
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both galactosylceramides and sulfatides contain high pro-
portions (up to 50%) of 2-hydroxy fatty acids ( 59 ). Surpris-
ingly, the FA2H mutations result in demyelination of the 
CNS, whereas PNS myelin abnormalities are not found, 
suggesting there is a second fatty acid 2-hydroxylating ac-
tivity in human Schwann cells ( 57 ). 
 Mouse models of glycosphingolipid disorders.  FA2H defi -
cient mouse mutants lack 2-hydroxylated sphingolipids 
[hydroxyl fatty acid (HFA)-GalC and HFA-sulfatide] as 
evaluated by thin-layer chromatography and MALDI-time-
of-fl ight (TOF) MS ( 60 ). The absence of 2-hydroxylated 
sphingolipids in mice does not cause any detectable my-
elin changes up to adulthood. However, myelin decom-
paction was detected in aged (18 months) brain and was 
even more severe in peripheral nerve samples where signs 
of myelin degeneration (e.g., decompaction and myelin 
loss) were observed, clearly suggesting a role of HFAs in 
long-term myelin stability. The presence of this discrete 
phenotype, or its late onset, suggests the possibility that 
other models of glycosphingolipid disorders, including a 
mouse model of Gaucher disease ( 61 ) or a knockout mouse 
for sphingomyelin synthase 2 ( 62 ), may have ultrastruc-
tural myelin changes that so far have not been detected. 
 The role of the most abundant galactosphingolipids in 
myelin was analyzed in mouse models disrupting either 
sulfatide biosynthesis alone [cerebroside sulfotransferase 
(CST) knockout mice] or disrupting both galactocerebro-
side and sulfatide biosynthesis [UDP-galactose:ceramide 
galactosyltransferase (CGT) knockout mice,  Fig. 4 ]. Char-
acterization of CST-defi cient mice revealed that sulfatide 
plays a crucial role in maintenance of myelin structure and 
organization of node and paranode ( 63, 64 ). Interestingly, 
whereas apparently normal myelin can be assembled in 
CST mutant animals, the myelin structure is disturbed 
with age, as refl ected by uncompacted myelin sheaths in 
the CNS and nodal and paranodal abnormalities in both 
the CNS and PNS. The defective sulfatide biosynthesis also 
leads to axonal changes, as demonstrated by the loss of 
large axons in the CNS and the presence of axonal protru-
sions in the PNS. In comparison, CGT mutant animals, 
which are unable to synthesize both galactocerebroside 
and sulfatide, have a similar but more marked myelin phe-
notype because myelin abnormalities (including uncom-
pacted areas and redundant myelin profi les) are already 
present at P10 and evolve to substantial demyelination at 
P43 ( 65 ). Both CGT   /   and CST   /   animals develop a 
similar nodal phenotype characterized by disorganized para-
nodal loops and enlarged nodal gaps ( 63 ). Because the 
CGT   /   animals accumulate HFA-Glc-Cer (which is nor-
mally absent) in their myelin, it was suggested that HFA-
Glc-Cer could compensate partially for the absence of 
galactolipids in these animals. However, inactivation of 
UDP-glucose ceramide glucosyltransferase (Ugcg), which 
prevented accumulation of HFA-Glc-Cer, did not lead to 
any aggravation of myelin phenotype in double knockout 
Ugcg fl ox/fl ox ; Cnp/Cre; CGT   /   mice ( 66 ). These data there-
fore suggest that glial cells are able to assemble myelin in 
the absence of glycolipids. 
 Fig.  4. Human inherited and mouse experimental defects in the 
glycosphingolipids synthesis pathway that cause myelin disorders. 
Solid line arrows depict direct link between two steps, dashed line 
arrow implies intermediate steps that are not shown. Dark gray 
ovals show positions of human diseases; light gray ovals show the 
position of mutated genes in experimental mouse models. ARSA, 
arylsulfatase A; ML, Metachromatic leukodystrophy; Cst, cerebro-
side sulfotransferase; GALC, galactosylceramidase; KD, Krabbe 
disease; Cgt, UDP-galactose:ceramide galactosyltransferase; Ugcg, 
UDP-glucose ceramide glucosyltransferase; SMPD1, sphingomyelin 
phosphodiesterase-1; NPD, Niemann-Pick disease type A; FA2H, 
fatty acid 2-hydroxylase; DLSP, Dysmyelinating leukodystrophy and 
spastic paraparesis with or without dystonia; Gal-Cer, galactocere-
broside; Glc-Cer: glucocerebroside; 2-OH FA, 2-hydroxy fatty acids; 
FA, fatty acids. 
by (albeit thin) myelin. These data have been corrobo-
rated by in vitro experiments showing that extracellular 
cholesterol increased myelination in both wild-type and 
mutant Schwann cells ( 52 ). Interestingly, detailed ultra-
structural and biochemical analysis of mutant myelin re-
vealed substantial increase in the amount of noncompact 
myelin, probably as a consequence of defective myelin 
protein transport from the endoplasmic reticulum to the 
myelin sheath (see below). These data, together with a syn-
chronized downregulation of the mRNA expression for 
multiple myelin proteins, suggest that in addition to its 
role as a major structural component of myelin, choles-
terol plays a crucial role in coordinating myelin membrane 
assembly. 
 Glycosphingolipid disorders 
 Most of the myelin defects in glycosphingolipid disor-
ders are due to accumulation of glycosphingolipids or 
their precursors ( Table 2 ). Metachromatic leukodystro-
phy, Krabbe disease, and Niemann-Pick disease type A 
lead to the accumulation of respectively sulfatides, galac-
tocerebrosides (and sphingosine), and sphingomyelin 
[( 53–56 )  Fig. 4 ) . The accumulation of these lipids in my-
elinating glial cells leads predominantly to cytotoxicity 
and demyelination. Myelin defects present in dysmyelinat-
ing leukodystrophy and spastic paraparesis with or without 
dystonia ( 57, 58 ), which is caused by a mutation in the 
gene encoding fatty acid 2-hydroxylase (FA2H), are, how-
ever, probably a consequence of reduced glycosphingo-
lipid levels. The 2-hydroxylation of sphingolipid  N -acyl 
chains catalyzed by the FA2H occurs during de novo cer-
amide synthesis. In accordance with the high level of FA2H 
in mammalian central and peripheral nervous systems, 
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panied by progressive loss of CNS and PNS myelin levels 
from early adulthood on and dysmyelination predomi-
nantly in the PNS. It remains to be determined whether 
myelinating glial cells are the primary cause, but these 
data are indicative of the involvement of VLCFA in main-
tenance of the myelin membrane ( 75 ). 
 Several mouse models have been generated for differ-
ent peroxisomal disorders. Many of those recapitulate the 
main pathological or biochemical defects observed in pa-
tients, most often associated with lipotoxicity caused by 
accumulation of metabolic intermediates, like VLCFA in 
RD and in ALD ( 76–81 ). It should be noted that satu-
rated VLCFAs, which are enriched in myelin ( Fig. 2 ), rely 
fully on peroxisomes for   -oxidation, which could under-
lie the vulnerability of myelin for VLCFA accumulation in 
these disorders. Peroxisome biogenesis disorders have 
been modeled by inactivating different Pex genes (Pex2, 
Pex5, Pex13), which resulted in an early postnatal death of 
affected animals, preventing myelin analysis ( 78–81 ). Mice 
carrying an oligodendrocyte specifi c deletion of Pex 5 
(CNPcre-Pex5 ( 82 )) assembled normal myelin, but sur-
prisingly within a few months, developed axonal defects 
followed by infl ammatory demyelination. The observation 
that the PEX5-defi cient oligodendrocytes are not able to 
maintain axonal integrity, even in the absence of obvious 
demyelination, indicates a role of oligodendrocyte peroxi-
some-associated lipid metabolism in axonal support. In 
addition, the remarkable infl ammatory demyelination ob-
served in CNPcre-Pex5 mice suggest a role for abnormal 
lipid metabolism in infl ammation ( 82 ), as also observed in 
human ALD disease ( 72, 83, 84 ). Interestingly, polyunsat-
urated VLCFAs, such as arachidonic acid, are substrates 
for the synthesis of eicosanoids, which are lipid infl amma-
tory mediators ( 85, 86 ). Peroxisomes play a major role in 
the degradation of eicosanoids ( 72, 87, 88 ). The fact that 
the VLCFAs in myelin are saturated and not unsaturated 
might reduce the risk of generating too high levels of lipid 
infl ammatory mediators. Together, these data suggest that 
peroxisomes in myelinating glial cells are likely to be im-
portant for protection against lipid induced infl ammation, 
by degrading VLCFA and eicosanoids. The observations 
on CNP-cre-PEX5 mice furthermore indicate that peroxi-
some-associated lipid metabolism is not required in oligo-
dendrocytes for myelin membrane synthesis per se. However, 
 Fatty acid and plasmalogen disorders 
 S everal disorders in fatty acid metabolism are associated 
with defects in myelin that are mostly caused by the accu-
mulation of lipids ( Table 2 ,  Fig. 5 ). In Sjogren-Larsson 
syndrome (SLS) mutations in fatty aldehyde dehydroge-
nase result in the accumulation of long-chain fatty alco-
hols ( 67 ), leading to CNS white matter abnormalities that 
are related to dysmyelination and hypomyelination ( 68, 
69 ). Lipid accumulation is also found in peroxisome 
disorders, such as Refsum disease [RD ( 70 )], adrenoleu-
kodystrophy [ALD ( 53 )], and peroxisome biogenesis 
disorders ( 71 ). In RD, mutation of phytanoyl-CoA hydrox-
ylase leads to the accumulation of phytanic acid, a plant-
derived fatty acid that is normally degraded by   -oxidation 
in peroxisomes. Accumulation of phytanic acid causes de-
myelination, especially in the PNS. ALD is caused by muta-
tion of the ABCD1 protein which functions as a transporter 
for the uptake of very long-chain fatty acids (VLCFAs) in 
peroxisomes. Because VLCFAs are metabolized in peroxi-
somes via   -oxidation, myelinating glial cells in ALD-
patients accumulate VLCFA, which causes dysmyelination 
but also infl ammatory-induced demyelination. The latter 
may be caused by the failure to degrade arachidonic acid-
derived eicosanoids ( 72, 73 ). Peroxisome biogenesis disor-
ders of Zellweger syndrome occur when any one of 12 
peroxins involved in the import of peroxisomal proteins is 
mutated [for a recent review, see ( 74 )]. The consequent 
partial or complete peroxisome dysfunction results in de-
fective   - and   -oxidation, subsequent accumulation of 
fatty acids, leading to myelin defects as also seen in ALD or 
RD. In addition, myelin defects due to reduced lipid levels 
are found in Zellweger syndrome as well, because the per-
oxisomal anabolic lipid pathway involved in ether lipid 
synthesis is disrupted ( Fig. 5 ), resulting in plasmalogen de-
fi ciency and consequent mild hypomyelination and dys-
myelination, especially in the CNS. 
 Mouse models of fatty acid disorders.  As shown in  Fig. 2 , 
myelin is specifi cally enriched in saturated VLCFAs (C22:0-
C24:0). Mice carrying a deletion of ceramide synthase 2, 
an enzyme that is mostly involved in synthesis of ceramides 
with VLCFAs, show myelin with ceramide species that no 
longer have VLCFAs (  C22) but instead are enriched in 
short-chain fatty acids ( 75 ). These changes where accom-
 Fig.  5. Human inherited and mouse experimental 
defects in fatty acids and plasmalogen metabolism 
that cause myelin disorders. Solid line arrows depict 
direct link between two steps, dashed line arrow im-
plies intermediate steps that are not shown. Dashed 
line rectangles represent various lipid metabolic path-
ways in the peroxisome. Dark gray ovals show posi-
tions of human disease genes; light gray ovals show 
the position of mutated genes in experimental mouse 
models. Dhapat, dihydroxyacetone phosphate acyl-
transferase; PHYH, phytanoyl-CoA hydroxylase; RD, 
Refsum disease; PEX1-12, peroxins; PBD, peroxisome 
biogenesis disorders; ALDH3A2, fatty aldehyde dehy-
drogenase; SLS, Sjogren-Larsson syndrome; ABCD1, 
ATP-binding cassette transporter D1; ALD, adreno-
leukodystrophy; VLCFA, very long-chain fatty acids. 
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 Mouse models of general lipid disorders.  Two mouse mod-
els of CD, in which ASPA is deleted, show myelin vacuoliza-
tion similar to human Canavan patients ( 102, 103 ), and 
reduced brain levels for acetate, myelin lipids, and myelin 
proteins ( 104, 105 ). Labeling studies have shown that NAA 
is a major source of acetate for lipid synthesis during brain 
development and that neuronal-derived NAA supplies ace-
tyl groups for myelin lipid synthesis ( 106, 107 ). Its quanti-
tative signifi cance for myelin synthesis is not completely 
clear because in most cell types, the enzyme ATP-citrate lyase 
provides the acetyl groups for fatty acid synthesis. Madha-
varao and colleagues ( 104 ) recently suggested that the 
lowering of acetate in ASPA knockout mice is suffi cient to 
decrease myelin synthesis. However, ultrastructural analy-
sis of myelin during development remains to be done in 
order to determine the precise consequence of ASPA defi -
ciency on myelin formation. Recently, it was shown that 
defective survival and differentiation of immature oligo-
dendrocytes may also be implicated in CD ( 108 ). Further-
more, the toxic effects of NAA in myelin vacuolization should 
not be neglected ( 109 ). 
 The role of glial lipid synthesis in myelination was re-
cently studied by Verheijen et al. ( 110 ). It was shown that 
the acute phase of myelin lipid synthesis is regulated by 
sterol regulatory element-binding protein (SREBP) cleav-
age activating protein (SCAP), an activator of SREBPs. 
mice in which Pex5 is lacking in all neural cells [Nestin-cre 
PEX5 mice ( 80 )] do show dysmyelination, indicating that, 
in CNP-cre-PEX5 mice, oligodendrocytes may take up per-
oxisome-derived lipids from other neural cells and utilize 
these lipids for myelin membrane synthesis. 
 Mouse models of plasmalogen disorders.  The Pex2, Pex5, 
or Pex13 knockout mouse models of peroxisome biogene-
sis disorder have reduced nervous system plasmalogen lev-
els ( 78–81 ), but how this contributes to myelin lipid defects 
is diffi cult to establish due to the contribution of the other 
defects in peroxisome lipid metabolism ( Fig. 5 ). The Pex7 
( 77 ) and dihydroxyacetone phosphate acyl transferase 
( 89 ) knockout mice were generated as mouse models of 
rhizomeluic chondrodysplasia type 1 and 2, respectively, 
both peroxisomal disorders that are characterized by a 
shortage of ether lipids and delays in myelination ( 80 ). In 
Pex7 knockout mice, a small reduction in CNS myelin pro-
tein levels was observed, and PNS nerves showed thinning 
of the myelin sheath and a reduced motor nerve conduc-
tion velocity ( 76 ). In the knockout mouse for Dhapat, a 
peroxisomal enzyme essential for plasmalogen synthesis, 
reduced CNS myelination was observed together with ab-
normal paranodal structure and reduced corpus callosum 
conduction velocity ( 90 ). Together, these studies suggest a 
structural role of plasmalogens in myelin membrane, al-
though ultrastructural studies remain necessary to unravel 
the precise role of plasmalogens in myelination. Further-
more, plasmalogens are described to function as a sink of 
polyunsaturated fatty acids (PUFAs) ( 91 ) and as such pro-
posed to have a protective role against the effects of 
PUFA accumulation as seen in peroxisome disorders 
( 92 ). Indeed, Pex7:Abcd1 knockout mice show an in-
crease in VLCFA accumulation and infl ammatory demy-
elination ( 76 ). 
 General lipogenesis disorders 
 Several myelin disorders are caused by defects in early 
steps in the synthesis of lipids ( Table 2 ,  Fig. 6 ). Pyruvate 
carboxylase defi ciency [PCD ( 93, 94 )] is caused by a muta-
tion in pyruvate carboxylase, an enzyme required for the 
synthesis of oxaloacetate of pyruvate in the tricarboxylic 
acid cycle, which is found in glial cells, predominantly as-
trocytes ( 95–97 ). Several biochemical pathways rely on the 
tricarboxylic acid cycle, such as biosynthesis of fatty acids, 
nonessential amino acids, and gluconeogenesis. Conse-
quently, PCD patients show CNS hypomyelination, whereas 
PNS myelin defects have not been described. Canavan dis-
ease [CD ( 98 )] is caused by a mutation in aspartoacylase 
(ASPA), an enzyme that in the rodent nervous system was 
shown to be predominantly expressed in oligodendrocytes 
( 99 ) and is involved in the deacetylation of the nervous 
system specifi c metabolite N-acetylaspartic acid (NAA), 
thus generating free acetate in the brain. Patients affected 
by CD show accumulation of neuronal NAA and reduced 
levels of acetate in oligodendrocytes, the latter is generally 
thought to limit fatty acid and membrane lipid synthesis 
and to underlie the spongiform myelin degeneration, 
while leaving neurons intact ( 100, 101 ). 
 Fig.  6. Human inherited and mouse experimental defects in 
general lipid metabolism that cause myelin disorders. Solid line 
arrows depict direct link between two steps, dashed line arrows im-
plies intermediate steps that are not shown. Dashed line circle rep-
resents the citric acid cycle in mitochondria. Dark gray oval shows 
positions of human disease genes; light gray oval shows the position 
of mutated genes in an experimental mouse model. PC, pyruvate car-
boxylase; PCD, pyruvate carboxylase defi ciency; ASPA, asparto-
acetylase; CD, Canavan disease; NAA, N-acetylaspartic acid; FA, 
fatty acids. 
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 Glycosphingolipids consist of a ceramide backbone, 
formed by a long-chain fatty acyl residue linked by its am-
ide bond to a long-chain sphingosine base that binds the 
functional group galactosyl or sulfatide. They pack tightly 
and have the remarkable property that their fl uid/solid 
phase transition temperature is above body temperature, 
so that glycolipids have a solid ‘gel’ phase at body temper-
ature ( 118–120 ). Accordingly, CGT knockout mice, which 
lack glycosphingolipids, have increased myelin membrane 
fl uidity and therefore increased ion permeability, which 
may disrupt saltatory conduction ( 121 ). In addition to 
this, the anionic glycol group may provide an electronic 
shielding on the outside of the myelin membrane and 
thereby contribute to the electric isolation by the myelin 
membrane and thus nerve conduction velocity. Interest-
ingly, glycosphingolipids are solubilized by cholesterol 
( 122 ), and both lipids are predominantly present in the 
outer leafl et of the myelin membrane. Asymmetric distri-
bution of lipids between two bilayer leafl ets contributes to 
curving of membranes ( 122 ). This suggests a role of gly-
cosphingolipids and cholesterol in regulating fl uidity and 
curving of myelin membranes, which could be particularly 
relevant for the paranodal loops structure. In line with this 
is the nodal phenotype of galactolipids-lacking CGT and 
CST knockout mice ( 63 ). 
 Plasmalogens are a sub-class of ether phospholipids, 
which are glycerol-derived compounds that carry an ether-
linked carbohydrate chain on the fi rst carbon of glycerol 
as opposed to ester-linked fatty acid chain in classical phos-
pholipid containing a vinyl group next to the ether bond. 
The particular role of plasmalogens in membranes has not 
been elucidated, but they are thought to play a role in 
membrane fusion processes and membrane dynamics. 
They increase membrane fl uidity by lowering the transi-
tion of phospholipid mixtures from a lamellar to a liquid 
crystalline phase and stimulate the formation of nonbi-
layer lipid structures when present in high concentration 
( 123 ). Accordingly, plasmalogens could be involved in my-
elin membrane formation or maintenance by potentiating 
membrane dynamics ( 124 ). 
 The brain is enriched in long PUFAs like DHA (c22:6) 
( 125 ). However, this enrichment is not manifested in 
myelin, which instead contains high levels of saturated 
VLCFA, and has a particularly high C18:1/C18:2 ratio (see 
 Fig. 2 ). Because of its high degree of saturation, phospho-
lipids containing these fatty acids may decrease membrane 
fl uidity and give a higher degree of fatty acid ordering in 
the membrane, which prevents intercalation of polar mol-
ecules into the lipids. Together with the extra-long length 
of the acyl chains, this will provide a thick permeability 
barrier for ions and as such contribute to electric insula-
tion of the axon. 
 Considering their structural role in the membrane, we 
view that many of the lipids that are enriched in myelin 
play a role in its axon-insulating property: the electric 
shielding in the outer leafl et by glycolipids, the thick and 
ordered bilayer made by the long and saturated FA, and 
the further sealing of the outer leafl et by cholesterol. It 
should be noted that the specifi c myelin lipid composition 
P0cre-SCAP mice, which carry a Schwann cell specifi c de-
letion of SCAP, showed congenital hypomyelination, and 
had a loss of SREBP-mediated gene expression involved in 
cholesterol and fatty acids synthesis. Interestingly, SCAP 
mutant Schwann cells were able to slowly synthesize mye-
lin in an external lipid-dependent fashion, resulting in my-
elin membrane defects that were associated with abnormal 
lipid composition. Saturated VLCFAs (C22:0 and C24:0) 
were found to be reduced in myelin membranes, while 
poly-unsaturated fatty acids (C18:2, C22:6, C24:2, C25:2 
and C26:2) were increased. The reduced saturation level 
of long-chain fatty acids resulted in an increase in disorder 
of acyl groups in the myelin lipid bilayer, which may lead 
to altered packaging of proteins in the membrane ( 111 ) 
and consequent ultrastructural myelin abnormalities. 
These observations also showed that glial cells are able to 
take up lipids from the extracellular environment and uti-
lize these for myelin membrane synthesis, which is in line 
with the observation of Saher et al. ( 51, 52 ) on CNPcre-
SQS mice in which cholesterol defi cient myelinating glial 
cells are able to slowly synthesize myelin. 
 WHY ARE MYELINATING GLIAL CELLS 
PARTICULARLY VULNERABLE TO LIPID 
METABOLISM DISORDERS? 
 The unique lipid composition of myelin critically 
contributes to its function 
 Much of the vulnerability of myelin for lipid defects is 
caused by the fact that myelin membrane assembly re-
quires an extraordinary amount of lipids, especially for the 
lipids that are enriched in myelin: galactolipids, choles-
terol, plasmalogens, and fatty acids. As described above, 
for each of these lipid classes, human myelin disorders 
have been described in which the pathophysiology is re-
lated to lipotoxicity as a result of the accumulation of met-
abolic precursors for myelin lipids. The vulnerability of 
myelin for lipid disorders could, however, also relate to 
biochemical properties of each lipid class for functioning 
of the myelin membrane. 
 Cholesterol is one of the most important regulators of 
lipid organization in the membrane. The hydroxyl group 
of cholesterol interacts with the polar head group of other 
lipids, whereas the rigid body of cholesterol is situated 
along side the fatty acid tails of lipids in the membrane 
and can help to order these tails. The increased lateral 
ordering of lipids that is caused by cholesterol conse-
quently affects the biophysical properties of the membrane 
by decreasing fl uidity and reducing the permeability of 
polar molecules, like ions, for example ( 112–115 ). By con-
trast, too much ordering is detrimental because this could 
slow down the diffusion of membrane proteins and decrease 
the bending capacity of the membrane ( 112, 114, 116, 117 ). 
Furthermore, some membrane proteins bind tightly to 
cholesterol as discussed below. Together, this gives choles-
terol the capacity to regulate membrane fl uidity and to stabi-
lize and seal the membrane, all functions that seem critical 
for the insulating function of the myelin membrane ( 8 ). 
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ing glial cells are synthesizing most of the lipids themselves, 
but  2 ) myelinating glial cells are still able to synthesize my-
elin when endogenous lipid synthesis has been shut down, 
albeit at a very low level. This indicates that these cells have 
the capacity to take up lipids from the extracellular envi-
ronment. Accordingly, transcription analysis in rodents 
showed that lipoprotein receptors are expressed by oligo-
dendrocytes ( 127 ) and that expression of the low density 
lipoprotein receptor (LDLR) gene in the PNS is elevated 
with myelination ( 24 ) although the LDLR gene was found 
not to be required for PNS remyelination ( 128 ). Which li-
poprotein receptors are involved in the uptake of lipids 
and exactly where on the glial cell they can be found to 
support membrane growth ( Fig. 1 ) is currently unclear. 
The exact contribution of extracellular lipid supply for mye-
lin membrane synthesis under normal conditions remains 
to be determined, but is likely to be small ( Fig. 7 ). Defects 
in glial lipid synthesis will therefore consequently lead to 
defective myelin membrane synthesis. 
 Myelin lipids regulate the transport and localization of 
myelin proteins 
 In addition to the above mentioned synchronized ex-
pression of transcripts encoding structural myelin proteins 
and enzymes involved in myelin lipid biosynthesis, recent 
data suggest that glial lipid levels regulate myelin protein 
traffi cking and thus also myelin assembly ( 52 )( 129 ). In oli-
godendrocytes, proteolipid protein (PLP) associates with 
lipid rafts before exiting the Golgi apparatus, suggesting 
that myelin lipid and proteins assemble in the Golgi com-
plex. Indeed, the cholesterol- and galactosylceramide-rich 
lipid rafts were shown to be required for proper sorting of 
PLP to myelin ( 129 ). In line with this, certain mutations in 
PLP perturb interactions with cholesterol and lipid rafts, 
which may contribute to dysmyelination as found in spastic 
paraplegia ( 130 ). Similarly, disrupted Schwann cell cho-
lesterol biosynthesis led to partial mislocalization of my-
elin protein P0, resulting in noncompaction of the myelin 
membrane and hypomyelination ( 52 ). Additional cell cul-
ture experiments demonstrated that this defect could be 
restored by cholesterol supplementation, and showed the 
critical role of the myelin protein P0 cholesterol recogni-
tion/interaction amino acid consensus motif for its cor-
rect traffi cking from endoplasmic reticulum to the myelin 
compartment. Furthermore, elevation of extracellular cho-
lesterol or lipoprotein levels was demonstrated to increase 
myelination by Schwann cells in vitro ( 52, 110 ). Together, 
these data suggest that lipids may control myelin protein 
traffi cking and thereby assembly and compaction of the my-
elin membrane ( Fig. 7 ). This lipid-mediated control mech-
anism of myelin protein sorting is likely to be deregulated 
in lipid metabolic disorders, but whether and how it is used 
by myelinating glial cells to control myelin membrane syn-
thesis under healthy conditions remains to be determined. 
 Lipids regulate differentiation of myelinating glial cells 
 The regulatory role of lipids in differentiation of myeli-
nating glial cells was demonstrated in oligodendrocytes 
and in Schwann cells. Both the cell culture experiments 
is also likely to be related to proper packing of the myelin 
membrane. Changes in lipid composition affect lipid-
protein interactions causing an altered packing of proteins 
in the membrane ( 111 ). For instance, proteins and lipids 
may work synergistically to provide proper structure to my-
elin membranes ( 126 ). In line with this, interference with 
endogenous Schwann cell lipid metabolism in P0cre-SCAP 
mutant mice increases the unsaturation level of fatty acids 
in myelin and is accompanied by ultrastructural defects in 
myelin membrane packing ( 110 ). 
 Together, these data suggest that lipids may control in-
sulation of the axon and proper structure of the myelin 
membrane ( Fig. 7 ). Both of these aspects are clearly af-
fected in many lipid metabolic disorders, but it remains to 
be determined whether small functional defects on nerve 
function in certain cases are caused by more subtle changes 
in myelin lipid composition that affect axonal insulation. 
It is furthermore tempting to speculate that myelinating 
glial cells may control nerve conduction velocity by regula-
tion of its myelin lipid content. 
 Timely myelination requires extraordinarily high levels of 
lipid synthesis together with uptake of extracellular lipids 
 Much of the vulnerability of myelin for lipid defects is 
caused by the fact that myelin membrane assembly re-
quires an extraordinary amount of lipids. The observations 
on CNPcre-SQS ko mice ( 51, 52 ) and P0cre-SCAP ko mice 
( 110 ) have led to two important conclusions:  1 ) myelinat-
 Fig.  7. Schematic diagram of the various roles of lipids in myeli-
nating glial cells. Gray ovals show the processes that are affected by 
lipid metabolism and involved in myelinated fi ber function. High 
lipid levels, which are required for synthesis of a full myelin mem-
brane, are ensured by both the endogenous synthesis of lipids as by 
the uptake of lipids from the extracellular environment. Lipids infl u-
ence myelinating glial cell differentiation and traffi cking of myelin 
proteins to the myelin membrane. The unique lipid composition 
of the myelin membrane is required for proper myelin membrane 
wrapping (compaction) and electrostatic isolation of the axon from 
extracellular environment, thereby promoting saltatory conduc-
tion and conduction velocity. Question marks show processes with 
a potential effect on myelin fi ber function: the infl uence of lipid-
specifi c diets on myelin lipid dependent processes, and the possi-
ble role of myelin lipids in metabolic support of the axon. See text 
for further explanation. 
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somal biogenesis factor 5 (Pex5) led to generation of animals 
with disrupted peroxisomal function in oligodendrocytes 
and Schwann cells [see above ( 82 )]. Interestingly, al-
though the affected animals were able to assemble normal 
myelin, they developed progressive axonal loss followed by 
demyelination. Based on these data it was suggested that 
the observed axonal loss could be, at least partially, a con-
sequence of disrupted glial   -oxidation normally executed 
in peroxisomes, leading to a diminished capacity to meta-
bolically support the underlying axons ( 73 ). A similar hy-
pothesis suggesting the role of lipids in “energy-on-demand” 
supply for active axons was proposed based on expression 
analysis of genes encoding proteins involved in lipid me-
tabolism in the adult peripheral nerve ( 24, 136 ). Although 
further clarifi cation of the involvement of lipids in axonal 
support is still needed, it was shown that the expression of 
sterol response binding protein 1c (Srebp1c), which is the 
key transcriptional regulator of storage lipid metabolism, 
is affected in Schwann cells of a rodent model of diabetic 
peripheral neuropathy ( 137 ). Together, therefore, these 
data suggest that local glial lipid metabolism plays a crucial 
role not only in myelination but also in glial support of 
underlying axons. 
 Implications for therapeutic interventions that target 
lipid metabolism 
 A working strategy against lipotoxicity would be to use 
drugs that inhibit lipid accumulation. For instance, phar-
macological targeting of the cholesterol pathway, by statin-
induced inhibition of HMG-CoA reductase, is used in CTX 
to inhibit the accumulation of cholestan ( 138 ). Impor-
tantly, statins are widely used for the treatment of hyper-
cholesterolemia, and some statins, e.g., Lovastatin and 
Simvastatin, are able to cross the blood-brain barrier ( 139 ). 
Remarkably, statins can ameliorate remyelination in an 
animal model of multiple sclerosis (MS) ( 140–143 ), possi-
bly via augmenting survival and differentiation of oligo-
dendrocyte progenitors, and therefore have been tested in 
MS trials ( 144, 145 ). However, statins induce the forma-
tion of abnormal myelin-like membrane sheets in primary 
oligodendrocytes in vitro, due to impairment of cholesterol-
dependent myelin protein transport ( 146 ), which indi-
cates a risk of the use of statins for myelin membrane 
integrity. In addition, statins are reported to increase the 
risk of developing peripheral neuropathy ( 147 ), although 
there is some controversy concerning the exact amplitude 
of this risk, which furthermore appeared to be reversible 
and will need further study ( 148, 149 ). The major contri-
bution of endogenous lipid metabolism by myelinating 
glial cells implies that inhibition of glial lipid metabolism, 
especially during the active period of myelination, may un-
derlie the development of demyelinating neuropathy, and 
as such warrants for care in the use of lipid-lowering drugs 
especially during late pregnancies and early postnatal 
development. 
 Extracellular supply of lipids may be a working strategy 
for treatment of lipid defi cit in myelinating glial cells. Ob-
servations of mice with lipid-defi cient glial cells show that 
myelinating glial cells are able to take up lipids from the 
and the data from CGT and CST knockout animals re-
vealed an increased number of terminally differentiated 
oligodendrocytes (OLs) in the absence of galactosphingo-
lipids ( 131, 132 ). Based on these results, two putative reg-
ulatory mechanisms involving galactosphingolipids were 
suggested: either they could play a direct role in cell adhe-
sion necessary for correct timing of OL differentiation or 
they can have an indirect role affecting signaling proteins 
present in plasma membrane thus disturbing OL differen-
tiation ( 132 ). In the PNS, phosphatidic acid (PA) was shown 
to affect Schwann cell differentiation ( 133 ). Demyelina-
tion in Lpin1 mutant mice was suggested to be mediated 
by increased levels of PA. Subsequent cell culture experi-
ments demonstrated that PA induces Schwann cell dedif-
ferentiation via activation of the MEK-Erk pathway revealing 
its role in glial cell fate determination ( 133 ) ( Fig. 7 ). 
 MYELIN LIPIDS AS DETERMINANTS FOR 
NERVE FIBER FUNCTION 
 The process of myelination represents an interesting para-
digm to study the metabolism and transport of lipids. Myeli-
nation by rodent glial cells is, both in vivo and in vitro, 
fi nalized within a one- to two-week interval. Because during 
this period a myelinating glial cell needs to expand its mem-
brane up to 6,500 times, one can consider these cells as “lipid 
producing factories”. For instance, transcriptional analysis of 
myelinating glial cells clearly revealed that the most coregu-
lated group of genes expressed during the period of myelina-
tion are lipid biosynthesis-related transcripts ( 23, 24 ). 
 Lipids as markers for myelin membrane integrity 
and function 
 Much of the structure and function of myelin is depen-
dent on its lipid content. Lipids may therefore be used as 
markers for myelin membrane integrity and associated 
nerve fi ber function. The C18:1/C18:2 ratio is a well-
described marker for the progression of myelination of the 
PNS ( 7 ) and the CNS ( 134 ). In addition, a high level of 
PUFA in PNS myelin suggests a strong contribution of ex-
ogenous lipids in building of the myelin membrane ( 110 ). 
High cholesterol levels are required for the formation of 
compact myelin (with high P0), with low cholesterol levels 
resulting in increased amounts of noncompact myelin 
[with myelin-associated glycoprotein (MAG)] ( 52 ). This 
suggests that the cholesterol content of myelin is indica-
tive for its compaction status. Dedifferentiation of myeli-
nating Schwann cells in the Lpin1 mutant appeared to be 
mediated by high PA levels ( 133 ). This suggests that high 
PA levels are indicative for an active anti-myelination pro-
gram, although it remains to be determined whether PA 
is also instrumental in regulating (de)differentiation in 
other paradigms, e.g., during development or injury. 
 Myelin lipids provide direct support to axonal function; 
a hypothesis 
 A possible role of myelinating glial cells in trophic sup-
port of underlying axons was recently suggested ( 135 ). 
Previous data demonstrated that inactivation of peroxi-
 at Vrije Universiteit, Library, Dept. of Electronic Resources, on February 12, 2013
w
w
w
.jlr.org
D
ow
nloaded from
 
430 Journal of Lipid Research Volume 52, 2011
of local hypolipidemia induced by pathological conditions 
like genetic lipid disorders, myelinating glial cells may be 
able to obtain lipids derived from the circulation or from 
other nervous system compartments, albeit at a very low 
level. 
 As summarized in this review, our knowledge about the 
role of lipids in myelin biology increased substantially 
from the analysis of inherited myelin disorders with defec-
tive lipid metabolism and their related mouse models. 
These new data point to a far more complex role of lipids 
in myelinating glial cells than solely being building blocks 
for the myelin membrane ( Fig. 7 ). Lipid metabolism is im-
portant for glial cell development and function; lipids af-
fect glial cell differentiation, are involved in myelin protein 
traffi cking and myelin compaction, and may potentially 
contribute to mature myelinating glial cell support of en-
wrapped axons. Importantly, these new data also show that 
despite the requirement of timely local glial lipid synthesis 
for normal myelination, myelinating glial cells are able to 
take up lipids from the surrounding environment. To-
gether, these insights may contribute to the development 
of therapeutic approaches aiming at the preservation of 
myelin under pathological conditions that affect lipid me-
tabolism.  
 The authors thank Dr. J. F. Brouwers for advice and fatty acid 
analysis. 
 REFERENCES 
  1 .  Barres ,  B. A.  2008 .  The mystery and magic of glia: a perspective on 
their roles in health and disease.  Neuron .  60 :  430 – 440 . 
  2 .  Franz ,  D. N. , and  A.  Iggo .  1968 .  Conduction failure in myelinated 
and non-myelinated axons at low temperatures.  J. Physiol.  199 : 
 319 – 345 . 
  3 .  Waxman ,  S. G.  1980 .  Determinants of conduction velocity in mye-
linated nerve fi bers.  Muscle Nerve .  3 :  141 – 150 . 
  4 .  Hartline ,  D. K. , and  D. R.  Colman .  2007 .  Rapid conduction and 
the evolution of giant axons and myelinated fi bers.  Curr. Biol.  17 : 
 R29 – R35 . 
  5 .  Norton ,  W. T. , and  S. E.  Poduslo .  1973 .  Myelination in rat brain: 
method of myelin isolation.  J. Neurochem.  21 :  749 – 757 . 
  6 .  Norton ,  W. T. , and  S. E.  Poduslo .  1973 .  Myelination in rat brain: 
changes in myelin composition during brain maturation.  J. 
Neurochem.  21 :  759 – 773 . 
  7 .  Garbay ,  B. ,  A. M.  Heape ,  F.  Sargueil , and  C.  Cassagne .  2000 . 
 Myelin synthesis in the peripheral nervous system.  Prog. Neurobiol. 
 61 :  267 – 304 . 
  8 .  Saher ,  G. , and  M.  Simons .  2010 .  Cholesterol and myelin biogene-
sis.  Subcell. Biochem.  51 :  489 – 508 . 
  9 .  Norton ,  W. T. , and  W.  Cammer .  1984 . Isolation and characteriza-
tion of myelin.  In Myelin. P. Morell, editor. Plenum, New York. 
147–180. 
 10 .  Stoffel ,  W. , and  A.  Bosio .  1997 .  Myelin glycolipids and their func-
tions.  Curr. Opin. Neurobiol.  7 :  654 – 661 . 
 11 .  Eckhardt ,  M.  2008 .  The role and metabolism of sulfatide in the 
nervous system.  Mol. Neurobiol.  37 :  93 – 103 . 
 12 .  Nagan ,  N. , and  R. A.  Zoeller .  2001 .  Plasmalogens: biosynthesis 
and functions.  Prog. Lipid Res.  40 :  199 – 229 . 
 13 .  Balakrishnan ,  S. ,  H.  Goodwin , and  J. N.  Cumings .  1961 .  The dis-
tribution of phosphorus-containing lipid compounds in the hu-
man brain.  J. Neurochem.  8 :  276 – 284 . 
 14 .  Morell ,  P. , and R.H. Quarles.  1999 . Myelin formation, structure 
and biochemistry.  In Basic Neurochemistry. J. S. George, B. W. 
Agranoff, R. W. Albers, S. F. Fisher, and M. D. Uhler, editors. 
Lippincott-Raven, Philedelphia. 
extracellular environment ( 51, 52, 150 ). This is, however, 
complicated by the blood-nerve barrier and the blood-
brain barrier that shield, respectively, the PNS and CNS 
from lipids in the circulation ( 151, 152 ). Therefore, the 
nervous system is classically viewed as being largely autono-
mous in lipid metabolism. Despite this dogma, dietary ap-
proaches to rescue lipid defi cits are used in several lipid 
disorders to treat myelin defects. In SLOS, cholesterol 
supplementation leads to good biochemical and physical 
changes in nonneuronal tissues ( 153 ). Changes in neu-
ronal tissues are limited, also because of the inability to 
reverse developmental defects, although striking behav-
ioral improvements involving both CNS and PNS function-
ing were found ( 44, 45, 154 ). In a rodent model for CD, 
glyceryltriacetate supplementation was recently reported 
to improve motor performance and myelin lipid content 
( 155 ). In Zellweger patients, alkyl-glycerol supplementa-
tion to rescue plasmalogen defi ciency has been performed 
with only little success ( 156 ), which may be related to the 
other peroxisomal defects that are not related to plasmalo-
gen defi ciency in these patients. Interestingly, in Pex7 
knockout mice, a model for rhizomeluic chondrodysplasia 
type 1, alkyl-glycerol supplementation improves PNS plas-
malogen levels and nerve function (P. Brites, personal 
communication). 
 The above-described changes may not involve lipid up-
take by the nervous system, but instead be indirect conse-
quences of lipid supplementation. For instance, lipid 
metabolism in Schwann cells is under the infl uence of the 
nutritional status of mice through a mechanism probably 
involving insulin signaling ( 137 ). Recent studies have also 
shed light on novel mechanisms of cholesterol exchange 
between the CNS and circulating lipoproteins under cer-
tain physiological or pathological conditions. Saito et al. 
( 157 ) recently showed that deletion of SQS in neural 
stem cells led to neuronal cell death, however, not of pro-
genitor cells at the subventricular zone that protected 
themselves against cholesterol deprivation by promoting 
angiogenesis and consequently raising their lipoprotein 
cholesterol supply from the circulation. Furthermore, it 
was reported that specifi c loss of brain ABCA1, which is 
required for effl ux of cellular cholesterol, not only pro-
duced the expected reduction in brain cholesterol, but 
remarkably, also led to an apparently compensatory in-
crease in the specifi c uptake of esterifi ed cholesterol from 
plasma HDL particles into the CNS ( 158 ). The observed 
increase in HDL receptor SR-B1 in brain capillaries of 
these mice, together with the recent fi nding that lipopro-
tein receptors in brain capillary cells can be used for tar-
geting of compounds across the blood-brain barrier ( 159 ), 
indicate that the shielding of the CNS from circulating lip-
ids may not be as strict as thought for a long time. This is 
certainly the case for circulating unsaturated fatty acids. 
For instance, PNS myelin in P0cre-SCAP mutant mice con-
tains more polyunsaturated fatty acids, and have higher 
C18:2 levels, which is consistent with an increased uptake 
of essential fatty acids from external sources ( 160 ). Consis-
tent with this, circulating fatty acids are incorporated into 
adult myelin ( 161, 162 ). Taken together, in the situation 
 at Vrije Universiteit, Library, Dept. of Electronic Resources, on February 12, 2013
w
w
w
.jlr.org
D
ow
nloaded from
 
Lipids in myelinating glial cells 431
MRS fi ndings in Smith-Lemli-Opitz syndrome.  Neuroradiology .  46 : 
 3 – 14 . 
 37 .  Kelley ,  R. I. , and  R. C.  Hennekam .  2000 .  The Smith-Lemli-Opitz 
syndrome.  J. Med. Genet.  37 :  321 – 335 . 
 38 .  Curry ,  C. J. ,  J. C.  Carey ,  J. S.  Holland ,  D.  Chopra ,  R.  Fineman , 
 M.  Golabi ,  S.  Sherman ,  R. A.  Pagon ,  J.  Allanson ,  S.  Shulman ,  et al . 
 1987 .  Smith-Lemli-Opitz syndrome-type II: multiple congenital 
anomalies with male pseudohermaphroditism and frequent early 
lethality.  Am. J. Med. Genet.  26 :  45 – 57 . 
 39 .  Ryan ,  A. K. ,  K.  Bartlett ,  P.  Clayton ,  S.  Eaton ,  L.  Mills ,  D.  Donnai , 
 R. M.  Winter , and  J.  Burn .  1998 .  Smith-Lemli-Opitz syndrome: 
a variable clinical and biochemical phenotype.  J. Med. Genet.  35 : 
 558 – 565 . 
 40 .  Berry ,  R. ,  H.  Wilson ,  J.  Robinson ,  C.  Sandlin ,  W.  Tyson ,  J. 
 Campbell ,  R.  Porreco , and  D.  Manchester .  1989 .  Apparent Smith-
Lemli-Opitz syndrome and Miller-Dieker syndrome in a family 
with segregating translocation t(7;17)(q34;p13.1).  Am. J. Med. 
Genet.  34 :  358 – 365 . 
 41 .  Cherstvoy ,  E. D. ,  G. I.  Lazjuk ,  T. I.  Ostrovskaya ,  I. A.  Shved ,  G. I. 
 Kravtzova ,  I. W.  Lurie , and  A. I.  Gerasimovich .  1984 .  The Smith-
Lemli-Opitz syndrome. A detailed pathological study as a clue to a 
etiological heterogeneity.  Virchows Arch.  404 :  413 – 425 . 
 42 .  Ness ,  G. C. ,  D.  Lopez ,  O.  Borrego , and  E.  Gilbert-Barness .  1997 . 
 Increased expression of low-density lipoprotein receptors in a 
Smith-Lemli-Opitz infant with elevated bilirubin levels.  Am. J. 
Med. Genet.  68 :  294 – 299 . 
 43 .  Fierro ,  M. ,  A. J.  Martinez ,  J. W.  Harbison , and  S. H.  Hay .  1977 . 
 Smith-Lemli-Opitz syndrome: neuropathological and ophthalmo-
logical observations.  Dev. Med. Child Neurol.  19 :  57 – 62 . 
 44 .  Elias ,  E. R. ,  M. B.  Irons ,  A. D.  Hurley ,  G. S.  Tint , and  G.  Salen . 
 1997 .  Clinical effects of cholesterol supplementation in six pa-
tients with the Smith-Lemli-Opitz syndrome (SLOS).  Am. J. Med. 
Genet.  68 :  305 – 310 . 
 45 .  Irons ,  M. ,  E. R.  Elias ,  D.  Abuelo ,  M. J.  Bull ,  C. L.  Greene ,  V. P. 
 Johnson ,  L.  Keppen ,  C.  Schanen ,  G. S.  Tint , and  G.  Salen .  1997 . 
 Treatment of Smith-Lemli-Opitz syndrome: results of a multicen-
ter trial.  Am. J. Med. Genet.  68 :  311 – 314 . 
 46 .  Porter ,  F. D.  2000 .  RSH/Smith-Lemli-Opitz syndrome: a multi-
ple congenital anomaly/mental retardation syndrome due to an 
inborn error of cholesterol biosynthesis.  Mol. Genet. Metab.  71 : 
 163 – 174 . 
 47 .  Starck ,  L. ,  I.  Bjorkhem ,  E. M.  Ritzen ,  B. Y.  Nilsson , and  U.  von 
Dobeln .  1999 .  Benefi cial effects of dietary supplementation in a 
disorder with defective synthesis of cholesterol. A case report of 
a girl with Smith-Lemli-Opitz syndrome, polyneuropathy and pre-
cocious puberty.  Acta Paediatr.  88 :  729 – 733 . 
 48 .  Fitzky ,  B. U. ,  F. F.  Moebius ,  H.  Asaoka ,  H.  Waage-Baudet ,  L. 
 Xu ,  G.  Xu ,  N.  Maeda ,  K.  Kluckman ,  S.  Hiller ,  H.  Yu ,  et al .  2001 . 
 7-Dehydrocholesterol-dependent proteolysis of HMG-CoA reduc-
tase suppresses sterol biosynthesis in a mouse model of Smith-
Lemli-Opitz/RSH syndrome.  J. Clin. Invest.  108 :  905 – 915 . 
 49 .  Wassif ,  C. A. ,  P.  Zhu ,  L.  Kratz ,  P. A.  Krakowiak ,  K. P.  Battaile ,  F. F. 
 Weight ,  A.  Grinberg ,  R. D.  Steiner ,  N. A.  Nwokoro ,  R. I.  Kelley , 
 et al .  2001 .  Biochemical, phenotypic and neurophysiological 
characterization of a genetic mouse model of RSH/Smith–Lemli–
Opitz syndrome.  Hum. Mol. Genet.  10 :  555 – 564 . 
 50 .  Correa-Cerro ,  L. S. ,  C. A.  Wassif ,  L.  Kratz ,  G. F.  Miller ,  J. P. 
 Munasinghe ,  A.  Grinberg ,  S. J.  Fliesler , and  F. D.  Porter .  2006 . 
 Development and characterization of a hypomorphic Smith-
Lemli-Opitz syndrome mouse model and effi cacy of simvastatin 
therapy.  Hum. Mol. Genet.  15 :  839 – 851 . 
 51 .  Saher ,  G. ,  B.  Brugger ,  C.  Lappe-Siefke ,  W.  Mobius ,  R.  Tozawa , 
 M. C.  Wehr ,  F.  Wieland ,  S.  Ishibashi , and  K. A.  Nave .  2005 .  High 
cholesterol level is essential for myelin membrane growth.  Nat. 
Neurosci.  8 :  468 – 475 . 
 52 .  Saher ,  G. ,  S.  Quintes ,  W.  Mobius ,  M. C.  Wehr ,  E. M.  Kramer-
Albers ,  B.  Brugger , and  K. A.  Nave .  2009 .  Cholesterol regulates 
the endoplasmic reticulum exit of the major membrane protein 
P0 required for peripheral myelin compaction.  J. Neurosci.  29 : 
 6094 – 6104 . 
 53 .  von Figura ,  K. ,  V.  Gieselmann , and  J.  Jaeken .  2001 . Metachromatic 
leukodystrophy.  In The Metabolic And Molecular Basis of 
Inherited Disease. C. R. Scriver, A. L. Beaudet, D. Valle, W. S. Sly, 
editors. McGraw Hill, New York. 3695–3724. 
 54 .  Landrieu ,  P. , and  G.  Said .  1984 .  Peripheral neuropathy in type A 
Niemann-Pick disease. A morphological study.  Acta Neuropathol. 
 63 :  66 – 71 . 
 15 .  Sowell ,  E. R. ,  B. S.  Peterson ,  P. M.  Thompson ,  S. E.  Welcome ,  A. 
L.  Henkenius , and  A. W.  Toga .  2003 .  Mapping cortical change 
across the human life span.  Nat. Neurosci.  6 :  309 – 315 . 
 16 .  Yakovlev ,  P. I. , and  A. R.  Lecours .  1967 . The myelogenetic cycles 
of regional maturation of the brain.  In Regional Development of 
the Brain in Early Life. A. Minkowski, editor. Blackwell Scientifi c, 
Oxford. 3–70. 
 17 .  Muse ,  E. D. ,  H.  Jurevics ,  A. D.  Toews ,  G. K.  Matsushima , and  P. 
 Morell .  2001 .  Parameters related to lipid metabolism as markers 
of myelination in mouse brain.  J. Neurochem.  76 :  77 – 86 . 
 18 .  Baron ,  W. , and  D.  Hoekstra .  2009 .  On the biogenesis of myelin 
membranes: sorting, traffi cking and cell polarity.  FEBS Lett.  584 : 
 1760 – 1770 . 
 19 .  Webster ,  H. D.  1971 .  The geometry of peripheral myelin sheaths 
during their formation and growth in rat sciatic nerves.  J. Cell Biol. 
 48 :  348 – 367 . 
 20 .  Heape ,  A. ,  H.  Juguelin ,  M.  Fabre ,  F.  Boiron ,  B.  Garbay ,  M. 
 Fournier ,  J.  Bonnet , and  C.  Cassagne .  1986 .  Correlation between 
the morphology and the lipid and protein compositions in the 
peripheral nervous system of individual 8-day-old normal and 
trembler mice.  Brain Res.  390 :  173 – 180 . 
 21 .  Heape ,  A. ,  H.  Juguelin ,  M.  Fabre ,  F.  Boiron , and  C.  Cassagne . 
 1986 .  A quantitative developmental study of the peripheral nerve 
lipid composition during myelinogenesis in normal and trembler 
mice.  Brain Res.  390 :  181 – 189 . 
 22 .  Heape ,  A. ,  F.  Boiron , and  C.  Cassagne .  1987 .  A developmental 
study of fatty acyl group contents in the peripheral nervous system 
of normal and trembler mice.  Neurochem. Pathol.  7 :  157 – 167 . 
 23 .  Nagarajan ,  R. ,  N.  Le ,  H.  Mahoney ,  T.  Araki , and  J.  Milbrandt . 
 2002 .  Deciphering peripheral nerve myelination by using 
Schwann cell expression profi ling.  Proc. Natl. Acad. Sci. USA . 
 99 :  8998 – 9003 . 
 24 .  Verheijen ,  M. H. ,  R.  Chrast ,  P.  Burrola , and  G.  Lemke .  2003 .  Local 
regulation of fat metabolism in peripheral nerves.  Genes Dev.  17 : 
 2450 – 2464 . 
 25 .  Ando ,  S. ,  Y.  Tanaka ,  Y.  Toyoda , and  K.  Kon .  2003 .  Turnover of 
myelin lipids in aging brain.  Neurochem. Res.  28 :  5 – 13 . 
 26 .  Dyck ,  P. J. , and  P. K.  Thomas .  2005 . Lysosomal and peroxi-
somal disorders.  In Peripheral Neuropathy. Elsevier Saunders, 
Philadelphia, PA. 1845–1882. 
 27 .  Wanders ,  R. J. ,  S.  Ferdinandusse ,  P.  Brites , and  S.  Kemp .  2010 . 
 Peroxisomes, lipid metabolism and lipotoxicity.  Biochim. Biophys. 
Acta .  1801 :  272 – 280 . 
 28 .  Horster ,  F. ,  R.  Surtees , and  G. F.  Hoffmann .  2005 .  Disorders of 
intermediary metabolism: toxic leukoencephalopathies.  J. Inherit. 
Metab. Dis.  28 :  345 – 356 . 
 29 .  Verrips ,  A. ,  L. H.  Hoefsloot ,  G. C.  Steenbergen ,  J. P.  Theelen , 
 R. A.  Wevers ,  F. J.  Gabreels ,  B. G.  van Engelen , and  L. P.  van 
den Heuvel .  2000 .  Clinical and molecular genetic characteristics 
of patients with cerebrotendinous xanthomatosis.  Brain .  123 : 
 908 – 919 . 
 30 .  Gallus ,  G. N. ,  M. T.  Dotti , and  A.  Federico .  2006 .  Clinical and 
molecular diagnosis of cerebrotendinous xanthomatosis with 
a review of the mutations in the CYP27A1 gene.  Neurol. Sci.  27 : 
 143 – 149 . 
 31 .  Pietrini ,  V. ,  N.  Rizzuto ,  C.  Vergani ,  F.  Zen , and  F.  Ferro Milone . 
 1985 .  Neuropathy in Tangier disease: A clinicopathologic study 
and a review of the literature.  Acta Neurol. Scand.  72 :  495 – 505 . 
 32 .  Pollock ,  M. ,  H.  Nukada ,  R. W.  Frith ,  J. P.  Simcock , and  S.  Allpress . 
 1983 .  Peripheral neuropathy in Tangier disease.  Brain .  106 : 
 911 – 928 . 
 33 .  Neklason ,  D. W. ,  K. M.  Andrews ,  R. I.  Kelley , and  J. E.  Metherall . 
 1999 .  Biochemical variants of Smith-Lemli-Opitz syndrome.  Am. J. 
Med. Genet.  85 :  517 – 523 . 
 34 .  Witsch-Baumgartner ,  M. ,  B. U.  Fitzky ,  M.  Ogorelkova ,  H. G.  Kraft , 
 F. F.  Moebius ,  H.  Glossmann ,  U.  Seedorf ,  G.  Gillessen-Kaesbach , 
 G. F.  Hoffmann ,  P.  Clayton ,  et al .  2000 .  Mutational spectrum in 
the Delta7-sterol reductase gene and genotype-phenotype cor-
relation in 84 patients with Smith-Lemli-Opitz syndrome.  Am. J. 
Hum. Genet.  66 :  402 – 412 . 
 35 .  Ciara ,  E. ,  M. J.  Nowaczyk ,  M.  Witsch-Baumgartner ,  E.  Malunowicz , 
 E.  Popowska ,  A.  Jezela-Stanek ,  M.  Piotrowicz ,  J. S.  Waye ,  G. 
 Utermann , and  M.  Krajewska-Walasek .  2004 .  DHCR7 mutations 
and genotype-phenotype correlation in 37 Polish patients with 
Smith-Lemli-Opitz syndrome.  Clin. Genet.  66 :  517 – 524 . 
 36 .  Caruso ,  P. A. ,  T. Y.  Poussaint ,  A. A.  Tzika ,  D.  Zurakowski ,  L. G. 
 Astrakas ,  E. R.  Elias ,  C.  Bay , and  M. B.  Irons .  2004 .  MRI and 1H 
 at Vrije Universiteit, Library, Dept. of Electronic Resources, on February 12, 2013
w
w
w
.jlr.org
D
ow
nloaded from
 
432 Journal of Lipid Research Volume 52, 2011
 74 .  Van Veldhoven ,  P. P.  2010 .  Biochemistry and genetics of inher-
ited disorders of peroxisomal fatty acid metabolism.  J. Lipid Res. 
 51 :  2863 – 2895 . 
 75 .  Imgrund ,  S. ,  D.  Hartmann ,  H.  Farwanah ,  M.  Eckhardt ,  R. 
 Sandhoff ,  J.  Degen ,  V.  Gieselmann ,  K.  Sandhoff , and  K.  Willecke . 
 2009 .  Adult ceramide synthase 2 (CERS2)-defi cient mice exhibit 
myelin sheath defects, cerebellar degeneration, and hepatocarci-
nomas.  J. Biol. Chem.  284 :  33549 – 33560 . 
 76 .  Brites ,  P. ,  P. A.  Mooyer ,  L.  El Mrabet ,  H. R.  Waterham , and  R. J. 
 Wanders .  2009 .  Plasmalogens participate in very-long-chain fatty 
acid-induced pathology.  Brain .  132 :  482 – 492 . 
 77 .  Brites ,  P. ,  A. M.  Motley ,  P.  Gressens ,  P. A.  Mooyer ,  I.  Ploegaert , 
 V.  Everts ,  P.  Evrard ,  P.  Carmeliet ,  M.  Dewerchin ,  L.  Schoonjans , 
 et al .  2003 .  Impaired neuronal migration and endochondral os-
sifi cation in Pex7 knockout mice: a model for rhizomelic chon-
drodysplasia punctata.  Hum. Mol. Genet.  12 :  2255 – 2267 . 
 78 .  Maxwell ,  M. ,  J.  Bjorkman ,  T.  Nguyen ,  P.  Sharp ,  J.  Finnie ,  C. 
 Paterson ,  I.  Tonks ,  B. C.  Paton ,  G. F.  Kay , and  D. I.  Crane .  2003 . 
 Pex13 inactivation in the mouse disrupts peroxisome biogenesis 
and leads to a Zellweger syndrome phenotype.  Mol. Cell. Biol.  23 : 
 5947 – 5957 . 
 79 .  Faust ,  P. L. , and  M. E.  Hatten .  1997 .  Targeted deletion of the 
PEX2 peroxisome assembly gene in mice provides a model for 
Zellweger syndrome, a human neuronal migration disorder.  J. Cell 
Biol.  139 :  1293 – 1305 . 
 80 .  Baes ,  M. , and  P.  Aubourg .  2009 .  Peroxisomes, myelination, and 
axonal integrity in the CNS.  Neuroscientist .  15 :  367 – 379 . 
 81 .  Baes ,  M. ,  P.  Gressens ,  E.  Baumgart ,  P.  Carmeliet ,  M.  Casteels , 
 M.  Fransen ,  P.  Evrard ,  D.  Fahimi ,  P. E.  Declercq ,  D.  Collen , 
 et al .  1997 .  A mouse model for Zellweger syndrome.  Nat. Genet. 
 17 :  49 – 57 . 
 82 .  Kassmann ,  C. M. ,  C.  Lappe-Siefke ,  M.  Baes ,  B.  Brugger , 
 A.  Mildner ,  H. B.  Werner ,  O.  Natt ,  T.  Michaelis ,  M.  Prinz , 
 J.  Frahm ,  et al .  2007 .  Axonal loss and neuroinfl ammation 
caused by peroxisome-defi cient oligodendrocytes.  Nat. Genet. 
 39 :  969 – 976 . 
 83 .  Powers ,  J. M. ,  Y.  Liu ,  A. B.  Moser , and  H. W.  Moser .  1992 .  The 
infl ammatory myelinopathy of adreno-leukodystrophy: cells, ef-
fector molecules, and pathogenetic implications.  J. Neuropathol. 
Exp. Neurol.  51 :  630 – 643 . 
 84 .  Ito ,  M. ,  B. M.  Blumberg ,  D. J.  Mock ,  A. D.  Goodman ,  A. B.  Moser , 
 H. W.  Moser ,  K. D.  Smith , and  J. M.  Powers .  2001 .  Potential 
environmental and host participants in the early white matter 
lesion of adreno-leukodystrophy: morphologic evidence for 
CD8 cytotoxic T cells, cytolysis of oligodendrocytes, and CD1-
mediated lipid antigen presentation.  J. Neuropathol. Exp. Neurol. 
 60 :  1004 – 1019 . 
 85 .  elMasry ,  M. N. , and  R. R.  Rich .  1989 .  Prostaglandin E2 selectively 
increases interferon gamma receptor expression on human CD8+ 
lymphocytes.  J. Clin. Invest.  83 :  1436 – 1440 . 
 86 .  Jozefowski ,  S. ,  R.  Biedron ,  M.  Bobek , and  J.  Marcinkiewicz .  2005 . 
 Leukotrienes modulate cytokine release from dendritic cells. 
 Immunology .  116 :  418 – 428 . 
 87 .  Schepers ,  L. ,  M.  Casteels ,  J.  Vamecq ,  G.  Parmentier ,  P. P.  Van 
Veldhoven , and  G. P.  Mannaerts .  1988 .  Beta-oxidation of the car-
boxyl side chain of prostaglandin E2 in rat liver peroxisomes and 
mitochondria.  J. Biol. Chem.  263 :  2724 – 2731 . 
 88 .  Ferdinandusse ,  S. ,  T.  Meissner ,  R. J.  Wanders , and  E.  Mayatepek . 
 2002 .  Identifi cation of the peroxisomal beta-oxidation enzymes 
involved in the degradation of leukotrienes.  Biochem. Biophys. Res. 
Commun.  293 :  269 – 273 . 
 89 .  Rodemer ,  C. ,  T. P.  Thai ,  B.  Brugger ,  T.  Kaercher ,  H.  Werner ,  K. 
A.  Nave ,  F.  Wieland ,  K.  Gorgas , and  W. W.  Just .  2003 .  Inactivation 
of ether lipid biosynthesis causes male infertility, defects in eye de-
velopment and optic nerve hypoplasia in mice.  Hum. Mol. Genet. 
 12 :  1881 – 1895 . 
 90 .  Teigler ,  A. ,  D.  Komljenovic ,  A.  Draguhn ,  K.  Gorgas , and  W. W. 
 Just .  2009 .  Defects in myelination, paranode organization and 
Purkinje cell innervation in the ether lipid-defi cient mouse cere-
bellum.  Hum. Mol. Genet.  18 :  1897 – 1908 . 
 91 .  Tamby ,  J. P. ,  P.  Reinaud , and  G.  Charpigny .  1996 .  Preferential es-
terifi cation of arachidonic acid into ethanolamine phospholipids 
in epithelial cells from ovine endometrium.  J. Reprod. Fertil.  107 : 
 23 – 30 . 
 92 .  Brites ,  P. ,  H. R.  Waterham , and  R. J.  Wanders .  2004 .  Functions 
and biosynthesis of plasmalogens in health and disease.  Biochim. 
Biophys. Acta .  1636 :  219 – 231 . 
 55 .  Suzuki ,  K.  2003 .  Globoid cell leukodystrophy (Krabbe’s disease): 
update.  J. Child Neurol.  18 :  595 – 603 . 
 56 .  Schuchman ,  E. H. , and  R. J.  Desnick .  2001 . Niemann-Pick dis-
ease types A and B: acid sphingomyelinase defi ciencies.  In The 
Metabolic and Molecular Basis of Inherited Disease. C. R. Scriver, 
A. L. Beaudet, W. S. Sly, D. Valle, B. Childs, K. W. Kinzler, and B. 
Vogelstein, editors. McGraw-Hill, New York. 3589–3610. 
 57 .  Edvardson ,  S. ,  H.  Hama ,  A.  Shaag ,  J. M.  Gomori ,  I.  Berger ,  D. 
 Soffer ,  S. H.  Korman ,  I.  Taustein ,  A.  Saada , and  O.  Elpeleg .  2008 . 
 Mutations in the fatty acid 2-hydroxylase gene are associated with 
leukodystrophy with spastic paraparesis and dystonia.  Am. J. Hum. 
Genet.  83 :  643 – 648 . 
 58 .  Dick ,  K. J. ,  M.  Eckhardt ,  C.  Paisan-Ruiz ,  A. A.  Alshehhi ,  C. 
 Proukakis ,  N. A.  Sibtain ,  H.  Maier ,  R.  Sharifi  ,  M. A.  Patton ,  W. 
 Bashir ,  et al .  2010 .  Mutation of FA2H underlies a complicated 
form of hereditary spastic paraplegia (SPG35).  Hum. Mutat.  31 : 
 E1251 – E1260 . 
 59 .  Alderson ,  N. L. ,  B. M.  Rembiesa ,  M. D.  Walla ,  A.  Bielawska ,  J. 
 Bielawski , and  H.  Hama .  2004 .  The human FA2H gene encodes a 
fatty acid 2-hydroxylase.  J. Biol. Chem.  279 :  48562 – 48568 . 
 60 .  Zoller ,  I. ,  M.  Meixner ,  D.  Hartmann ,  H.  Bussow ,  R.  Meyer ,  V. 
 Gieselmann , and  M.  Eckhardt .  2008 .  Absence of 2-hydroxylated 
sphingolipids is compatible with normal neural development 
but causes late-onset axon and myelin sheath degeneration.  J. 
Neurosci.  28 :  9741 – 9754 . 
 61 .  Enquist ,  I. B. ,  C.  Lo Bianco ,  A.  Ooka ,  E.  Nilsson ,  J. E.  Mansson ,  M. 
 Ehinger ,  J.  Richter ,  R. O.  Brady ,  D.  Kirik , and  S.  Karlsson .  2007 . 
 Murine models of acute neuronopathic Gaucher disease.  Proc. 
Natl. Acad. Sci. USA .  104 :  17483 – 17488 . 
 62 .  Hailemariam ,  T. K. ,  C.  Huan ,  J.  Liu ,  Z.  Li ,  C.  Roman ,  M. 
 Kalbfeisch ,  H. H.  Bui ,  D. A.  Peake ,  M. S.  Kuo ,  G.  Cao ,  et al .  2008 . 
 Sphingomyelin synthase 2 defi ciency attenuates NFkappaB activa-
tion.  Arterioscler. Thromb. Vasc. Biol.  28 :  1519 – 1526 . 
 63 .  Marcus ,  J. ,  S.  Honigbaum ,  S.  Shroff ,  K.  Honke ,  J.  Rosenbluth , and 
 J. L.  Dupree .  2006 .  Sulfatide is essential for the maintenance of 
CNS myelin and axon structure.  Glia .  53 :  372 – 381 . 
 64 .  Hoshi ,  T. ,  A.  Suzuki ,  S.  Hayashi ,  K.  Tohyama ,  A.  Hayashi ,  Y. 
 Yamaguchi ,  K.  Takeuchi , and  H.  Baba .  2007 .  Nodal protrusions, 
increased Schmidt-Lanterman incisures, and paranodal disorga-
nization are characteristic features of sulfatide-defi cient periph-
eral nerves.  Glia .  55 :  584 – 594 . 
 65 .  Coetzee ,  T. ,  N.  Fujita ,  J.  Dupree ,  R.  Shi ,  A.  Blight ,  K.  Suzuki , and 
 B.  Popko .  1996 .  Myelination in the absence of galactocerebroside 
and sulfatide: normal structure with abnormal function and re-
gional instability.  Cell .  86 :  209 – 219 . 
 66 .  Saadat ,  L. ,  J. L.  Dupree ,  J.  Kilkus ,  X.  Han ,  M.  Traka ,  R. L.  Proia , 
 G.  Dawson , and  B.  Popko .  2010 .  Absence of oligodendroglial 
glucosylceramide synthesis does not result in CNS myelin abnor-
malities or alter the dysmyelinating phenotype of CGT-defi cient 
mice.  Glia .  58 :  391 – 398 . 
 67 .  Rizzo ,  W. B. ,  G.  Carney , and  Z.  Lin .  1999 .  The molecular basis 
of Sjogren-Larsson syndrome: mutation analysis of the fatty alde-
hyde dehydrogenase gene.  Am. J. Hum. Genet.  65 :  1547 – 1560 . 
 68 .  Willemsen ,  M. A. ,  M.  Van Der Graaf ,  M. S.  Van Der Knaap ,  A. 
 Heerschap ,  P. H.  Van Domburg ,  F. J.  Gabreels , and  J. J.  Rotteveel . 
 2004 .  MR imaging and proton MR spectroscopic studies in 
Sjogren-Larsson syndrome: characterization of the leukoenceph-
alopathy.  AJNR Am. J. Neuroradiol.  25 :  649 – 657 . 
 69 .  van Domburg ,  P. H. ,  M. A.  Willemsen ,  J. J.  Rotteveel ,  J. G.  de Jong , 
 H. O.  Thijssen ,  A.  Heerschap ,  J. R.  Cruysberg ,  R. J.  Wanders ,  F. 
J.  Gabreels , and  P. M.  Steijlen .  1999 .  Sjogren-Larsson syndrome: 
clinical and MRI/MRS fi ndings in FALDH-defi cient patients. 
 Neurology .  52 :  1345 – 1352 . 
 70 .  Wierzbicki ,  A. S. ,  M. D.  Lloyd ,  C. J.  Schofi eld ,  M. D.  Feher , 
and  F. B.  Gibberd .  2002 .  Refsum’s disease: a peroxisomal dis-
order affecting phytanic acid alpha-oxidation.  J. Neurochem.  80 : 
 727 – 735 . 
 71 .  Steinberg ,  S. J. ,  G.  Dodt ,  G. V.  Raymond ,  N. E.  Braverman ,  A. B. 
 Moser , and  H. W.  Moser .  2006 .  Peroxisome biogenesis disorders. 
 Biochim. Biophys. Acta .  1763 :  1733 – 1748 . 
 72 .  Mayatepek ,  E. ,  M.  Baumann ,  T.  Meissner ,  F.  Hanefeld , and  G. C. 
 Korenke .  2003 .  Role of leukotrienes as indicators of the infl am-
matory demyelinating reaction in x–linked cerebral adrenoleu-
kodystrophy.  J. Neurol.  250 :  1259 – 1260 . 
 73 .  Kassmann ,  C. M. , and  K. A.  Nave .  2008 .  Oligodendroglial impact 
on axonal function and survival - a hypothesis.  Curr. Opin. Neurol. 
 21 :  235 – 241 . 
 at Vrije Universiteit, Library, Dept. of Electronic Resources, on February 12, 2013
w
w
w
.jlr.org
D
ow
nloaded from
 
Lipids in myelinating glial cells 433
 113 .  Sankaram ,  M. B. , and  T. E.  Thompson .  1990 .  Modulation of phos-
pholipid acyl chain order by cholesterol. A solid-state 2H nuclear 
magnetic resonance study.  Biochemistry .  29 :  10676 – 10684 . 
 114 .  Huang ,  J. , and  G. W.  Feigenson .  1999 .  A microscopic interaction 
model of maximum solubility of cholesterol in lipid bilayers. 
 Biophys. J.  76 :  2142 – 2157 . 
 115 .  Kakorin ,  S. ,  U.  Brinkmann , and  E.  Neumann .  2005 .  Cholesterol 
reduces membrane electroporation and electric deformation of 
small bilayer vesicles.  Biophys. Chem.  117 :  155 – 171 . 
 116 .  Pan ,  J. ,  S.  Tristram-Nagle , and  J. F.  Nagle .  2009 .  Effect of cho-
lesterol on structural and mechanical properties of membranes 
depends on lipid chain saturation.  Phys. Rev. E Stat. Nonlin. Soft 
Matter Phys.  80 :  021931 . 
 117 .  Hofsass ,  C. ,  E.  Lindahl , and  O.  Edholm .  2003 .  Molecular dynamics 
simulations of phospholipid bilayers with cholesterol.  Biophys. J. 
 84 :  2192 – 2206 . 
 118 .  Wang ,  T. Y. , and  J. R.  Silvius .  2003 .  Sphingolipid partitioning into 
ordered domains in cholesterol-free and cholesterol-containing 
lipid bilayers.  Biophys. J.  84 :  367 – 378 . 
 119 .  Kulkarni ,  K. ,  D. S.  Snyder , and  T. J.  McIntosh .  1999 .  Adhesion 
between cerebroside bilayers.  Biochemistry .  38 :  15264 – 15271 . 
 120 .  Ruocco ,  M. J. ,  D.  Atkinson ,  D. M.  Small ,  R. P.  Skarjune ,  E.  Oldfi eld , 
and  G. G.  Shipley .  1981 .  X-ray diffraction and calorimetric study 
of anhydrous and hydrated N-palmitoylgalactosylsphingosine (ce-
rebroside).  Biochemistry .  20 :  5957 – 5966 . 
 121 .   Bosio ,  A. ,  E.  Binczek ,  W. F.  Haupt , and  W.  Stoffel .  1998 .  Composi-
tion and biophysical properties of myelin lipid defi ne the neuro-
logical defects in galactocerebroside- and sulfatide-defi cient mice. 
 J. Neurochem.  70 :  308 – 315 . 
 122 .  van Meer ,  G. ,  D. R.  Voelker , and  G. W.  Feigenson .  2008 .  Membrane 
lipids: where they are and how they behave.  Nat. Rev. Mol. Cell Biol. 
 9 :  112 – 124 . 
 123 .  Glaser ,  P. E. , and  R. W.  Gross .  1994 .  Plasmenylethanolamine facil-
itates rapid membrane fusion: a stopped-fl ow kinetic investigation 
correlating the propensity of a major plasma membrane constit-
uent to adopt an HII phase with its ability to promote membrane 
fusion.  Biochemistry .  33 :  5805 – 5812 . 
 124 .  Glaser ,  P. E. , and  R. W.  Gross .  1995 .  Rapid plasmenylethano l-
amine-selective fusion of membrane bilayers catalyzed by an 
isoform of glyceraldehyde-3-phosphate dehydrogenase: discrimi-
nation between glycolytic and fusogenic roles of individual iso-
forms.  Biochemistry .  34 :  12193 – 12203 . 
 125 .  Sastry ,  P. S.  1985 .  Lipids of nervous tissue: composition and me-
tabolism.  Prog. Lipid Res.  24 :  69 – 176 . 
 126 .  Hu ,  Y. ,  I.  Doudevski ,  D.  Wood ,  M.  Moscarello ,  C.  Husted ,  C. 
 Genain ,  J. A.  Zasadzinski , and  J.  Israelachvili .  2004 .  Synergistic in-
teractions of lipids and myelin basic protein.  Proc. Natl. Acad. Sci. 
USA .  101 :  13466 – 13471 . 
 127 .  Zhao ,  S. ,  X.  Hu ,  J.  Park ,  Y.  Zhu ,  Q.  Zhu ,  H.  Li ,  C.  Luo ,  R.  Han , 
 N.  Cooper , and  M.  Qiu .  2007 .  Selective expression of LDLR and 
VLDLR in myelinating oligodendrocytes.  Dev. Dyn.  236 :  2708 – 2712 . 
 128 .  Goodrum ,  J. F. ,  K. A.  Fowler ,  J. D.  Hostettler , and  A. D.  Toews . 
 2000 .  Peripheral nerve regeneration and cholesterol reutiliza-
tion are normal in the low-density lipoprotein receptor knockout 
mouse.  J. Neurosci. Res.  59 :  581 – 586 . 
 129 .  Simons ,  M. ,  E. M.  Kramer ,  C.  Thiele ,  W.  Stoffel , and  J.  Trotter . 
 2000 .  Assembly of myelin by association of proteolipid protein 
with cholesterol- and galactosylceramide-rich membrane do-
mains.  J. Cell Biol.  151 :  143 – 154 . 
 130 .  Kramer-Albers ,  E. M. ,  K.  Gehrig-Burger ,  C.  Thiele ,  J.  Trotter , and 
 K. A.  Nave .  2006 .  Perturbed interactions of mutant proteolipid 
protein/DM20 with cholesterol and lipid rafts in oligodendroglia: 
implications for dysmyelination in spastic paraplegia.  J. Neurosci. 
 26 :  11743 – 11752 . 
 131 .  Bansal ,  R. ,  S.  Winkler , and  S.  Bheddah .  1999 .  Negative regula-
tion of oligodendrocyte differentiation by galactosphingolipids. 
 J. Neurosci.  19 :  7913 – 7924 . 
 132 .  Hirahara ,  Y. ,  R.  Bansal ,  K.  Honke ,  K.  Ikenaka , and  Y.  Wada . 
 2004 .  Sulfatide is a negative regulator of oligodendrocyte 
differentiation: development in sulfatide-null mice.  Glia .  45 : 
 269 – 277 . 
 133 .  Nadra ,  K. ,  A. S.  de Preux Charles ,  J. J.  Medard ,  W. T.  Hendriks , 
 G. S.  Han ,  S.  Gres ,  G. M.  Carman ,  J. S.  Saulnier-Blache ,  M. H. 
 Verheijen , and  R.  Chrast .  2008 .  Phosphatidic acid mediates demy-
elination in Lpin1 mutant mice.  Genes Dev.  22 :  1647 – 1661 . 
 134 .  Huether ,  G. ,  M.  Klapproth , and  V.  Neuhoff .  1986 .  Fatty acid co-
mposition of myelin lipids from developing rat forebrain and 
 93 .  Marin-Valencia ,  I. ,  C. R.  Roe , and  J. M.  Pascual .  2010 .  Pyruvate 
carboxylase defi ciency: mechanisms, mimics and anaplerosis.  Mol. 
Genet. Metab.  101 :  9 – 17 . 
 94 .  Schiff ,  M. ,  V.  Levrat ,  C.  Acquaviva ,  C.  Vianey-Saban ,  M. O. 
 Rolland , and  N.  Guffon .  2006 .  A case of pyruvate carboxylase de-
fi ciency with atypical clinical and neuroradiological presentation. 
 Mol. Genet. Metab.  87 :  175 – 177 . 
 95 .  Cesar ,  M. , and  B.  Hamprecht .  1995 .  Immunocytochemical exam-
ination of neural rat and mouse primary cultures using monoclo-
nal antibodies raised against pyruvate carboxylase.  J. Neurochem. 
 64 :  2312 – 2318 . 
 96 .  Shank ,  R. P. ,  G. S.  Bennett ,  S. O.  Freytag , and  G. L.  Campbell . 
 1985 .  Pyruvate carboxylase: an astrocyte-specifi c enzyme impli-
cated in the replenishment of amino acid neurotransmitter pools. 
 Brain Res.  329 :  364 – 367 . 
 97 .  Murin ,  R. ,  M.  Cesar ,  B. S.  Kowtharapu ,  S.  Verleysdonk , and  B. 
 Hamprecht .  2009 .  Expression of pyruvate carboxylase in cultured 
oligodendroglial, microglial and ependymal cells.  Neurochem. Res. 
 34 :  480 – 489 . 
 98 .  Namboodiri ,  A. M. ,  A.  Peethambaran ,  R.  Mathew ,  P. A.  Sambhu , 
 J.  Hershfi eld ,  J. R.  Moffett , and  C. N.  Madhavarao .  2006 .  Canavan 
disease and the role of N-acetylaspartate in myelin synthesis.  Mol. 
Cell. Endocrinol.  252 :  216 – 223 . 
 99 .  Madhavarao ,  C. N. ,  J. R.  Moffett ,  R. A.  Moore ,  R. E.  Viola ,  M. A. 
 Namboodiri , and  D. M.  Jacobowitz .  2004 .  Immunohistochemical 
localization of aspartoacylase in the rat central nervous system. 
 J. Comp. Neurol.  472 :  318 – 329 . 
 100 .  Adachi ,  M. ,  L.  Schneck ,  J.  Cara , and  B. W.  Volk .  1973 .  Spongy 
degeneration of the central nervous system (van Bogaert and 
Bertrand type; Canavan’s disease). A review.  Hum. Pathol.  4 : 
 331 – 347 . 
 101 .  Gascon ,  G. G. ,  P. T.  Ozand ,  A.  Mahdi ,  A.  Jamil ,  A.  Haider ,  J. 
 Brismar , and  M.  al-Nasser .  1990 .  Infantile CNS spongy degener-
ation–14 cases: clinical update.  Neurology .  40 :  1876 – 1882 . 
 102 .  Matalon ,  R. M. , and  K.  Michals-Matalon .  2000 .  Spongy degener-
ation of the brain, Canavan disease: biochemical and molecular 
fi ndings.  Front. Biosci.  5 :  D307 – D311 . 
 103 .  Traka ,  M. ,  R. L.  Wollmann ,  S. R.  Cerda ,  J.  Dugas ,  B. A.  Barres , 
and  B.  Popko .  2008 .  Nur7 is a nonsense mutation in the mouse 
aspartoacylase gene that causes spongy degeneration of the CNS. 
 J. Neurosci.  28 :  11537 – 11549 . 
 104 .  Madhavarao ,  C. N. ,  P.  Arun ,  J. R.  Moffett ,  S.  Szucs ,  S.  Surendran , 
 R.  Matalon ,  J.  Garbern ,  D.  Hristova ,  A.  Johnson ,  W.  Jiang ,  et al . 
 2005 .  Defective N-acetylaspartate catabolism reduces brain ace-
tate levels and myelin lipid synthesis in Canavan’s disease.  Proc. 
Natl. Acad. Sci. USA .  102 :  5221 – 5226 . 
 105 .  Ledeen ,  R. W. ,  J.  Wang ,  G.  Wu ,  Z. H.  Lu ,  G.  Chakraborty ,  M. 
 Meyenhofer ,  S. K.  Tyring , and  R.  Matalon .  2006 . Physiological 
role of N-acetylaspartate: contribution to myelinogenesis.  Adv. 
Exp. Med. Biol.  576 : 131–143; discussion 361–133. 
 106 .  Namboodiri ,  A. M. ,  J. R.  Moffett ,  P.  Arun ,  R.  Mathew ,  S. 
 Namboodiri ,  A.  Potti ,  J.  Hershfi eld ,  B.  Kirmani ,  D. M.  Jacobowitz , 
and  C. N.  Madhavarao .  2006 . Defective myelin lipid synthesis as a 
pathogenic mechanism of Canavan disease.  Adv. Exp. Med. Biol. 
 576 : 145–163; discussion 361–143. 
 107 .  Chakraborty ,  G. ,  P.  Mekala ,  D.  Yahya ,  G.  Wu , and  R. W.  Ledeen . 
 2001 .  Intraneuronal N-acetylaspartate supplies acetyl groups for 
myelin lipid synthesis: evidence for myelin-associated aspartoacy-
lase.  J. Neurochem.  78 :  736 – 745 . 
 108 .  Kumar ,  S. ,  J. C.  Biancotti ,  R.  Matalon , and  J.  de Vellis .  2009 .  Lack 
of aspartoacylase activity disrupts survival and differentiation of 
neural progenitors and oligodendrocytes in a mouse model of 
Canavan disease.  J. Neurosci. Res.  87 :  3415 – 3427 . 
 109 .  Baslow ,  M. H. , and  D. N.  Guilfoyle .  2009 .  Are astrocytes the miss-
ing link between lack of brain aspartoacylase activity and the 
spongiform leukodystrophy in Canavan disease?  Neurochem. Res. 
 34 :  1523 – 1534 . 
 110 .  Verheijen ,  M. H. ,  N.  Camargo ,  V.  Verdier ,  K.  Nadra ,  A. S.  de 
Preux Charles ,  J. J.  Medard ,  A.  Luoma ,  M.  Crowther ,  H.  Inouye , 
 H.  Shimano ,  et al .  2009 .  SCAP is required for timely and proper 
myelin membrane synthesis.  Proc. Natl. Acad. Sci. USA .  106 : 
 21383 – 21388 . 
 111 .  Lee ,  A. G.  2003 .  Lipid-protein interactions in biological mem-
branes: a structural perspective.  Biochim. Biophys. Acta .  1612 :  1 – 40 . 
 112 .  Simons ,  K. , and  W. L.  Vaz .  2004 .  Model systems, lipid rafts, 
and cell membranes.  Annu. Rev. Biophys. Biomol. Struct.  33 : 
 269 – 295 . 
 at Vrije Universiteit, Library, Dept. of Electronic Resources, on February 12, 2013
w
w
w
.jlr.org
D
ow
nloaded from
 
434 Journal of Lipid Research Volume 52, 2011
spinal cord: infl uence of experimental hyperphenylalaninaemia. 
 Neurochem. Res.  11 :  1303 – 1311 . 
 135 .  Nave ,  K. A.  2010 .  Myelination and the trophic support of long 
axons.  Natl. Rev.  11 :  275 – 283 . 
 136 .  Chrast ,  R. ,  M. H.  Verheijen , and  G.  Lemke .  2004 .  Complement 
factors in adult peripheral nerve: a potential role in energy me-
tabolism.  Neurochem. Int.  45 :  353 – 359 . 
 137 .  de Preux ,  A. S. ,  K.  Goosen ,  W.  Zhang ,  A. A.  Sima ,  H.  Shimano , 
 D. M.  Ouwens ,  M.  Diamant ,  J. L.  Hillebrands ,  J.  Rozing ,  G. 
 Lemke ,  et al .  2007 .  SREBP-1c expression in Schwann cells is 
affected by diabetes and nutritional status.  Mol. Cell. Neurosci. 
 35 :  525 – 534 . 
 138 .  Verrips ,  A. ,  R. A.  Wevers ,  B. G.  Van Engelen ,  A.  Keyser ,  B. G. 
 Wolthers ,  F.  Barkhof ,  A.  Stalenhoef ,  R.  De Graaf ,  F.  Janssen-
Zijlstra ,  A.  Van Spreeken ,  et al .  1999 .  Effect of simvastatin in addi-
tion to chenodeoxycholic acid in patients with cerebrotendinous 
xanthomatosis.  Metabolism .  48 :  233 – 238 . 
 139 .  Saheki ,  A. ,  T.  Terasaki ,  I.  Tamai , and  A.  Tsuji .  1994 .  In vivo and in 
vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl 
coenzyme A (HMG-CoA) reductase inhibitors.  Pharm. Res.  11 : 
 305 – 311 . 
 140 .  Paintlia ,  A. S. ,  M. K.  Paintlia ,  M.  Khan , T.  Vollmer ,  A. K.  Singh , 
and  I.  Singh .  2005 .  HMG-CoA reductase inhibitor augments sur-
vival and differentiation of oligodendrocyte progenitors in animal 
model of multiple sclerosis .  Faseb. J.  19 :  1407 – 1421 . 
 141 .  Paintlia , A. S. ,  M. K.  Paintlia , A. K.  Singh , and  I.  Singh .  2008 . 
 Inhibition of rho family functions by lovastatin promotes myelin 
repair in ameliorating experimental autoimmune encephalomy-
elitis.  Mol. Pharmacol.  73 :  1381 – 1393 . 
 142 .  Stanislaus ,  R. ,  A. G.  Gilg ,  A. K.  Singh , and  I.  Singh .  2002 .  Immu-
nomodulation of experimental autoimmune encephalomyelitis 
in the Lewis rats by Lovastatin.  Neurosci. Lett.  333 :  167 – 170 . 
 143 .  Youssef ,  S. ,  O.  Stuve ,  J. C.  Patarroyo ,  P. J.  Ruiz ,  J. L.  Radosevich ,  E. 
M.  Hur ,  M.  Bravo ,  D. J.  Mitchell ,  R. A.  Sobel ,  L.  Steinman , and  S. 
S.  Zamvil .  2002 .  The HMG-CoA reductase inhibitor, atorvastatin, 
promotes a Th2 bias and reverses paralysis in central nervous sys-
tem autoimmune disease.  Nature.  420 :  78 – 84 . 
 144 .  Sena ,  A. ,  R.  Pedrosa , and  M.  Graca Morais .  2003 .  Therapeutic po-
tential of lovastatin in multiple sclerosis.  J. Neurol.  250 :  754 – 755 . 
 145 .  Vollmer ,  T. ,  L.  Key ,  V.  Durkalski , W.  Tyor ,  J.  Corboy ,  S.  Markovic-
Plese ,  J.  Preiningerova ,  M.  Rizzo , and  I.  Singh .  2004 .  Oral simvas-
tatin treatment in relapsing-remitting multiple sclerosis .  Lancet. 
 363 :  1607 – 1608 . 
 146 .  Maier ,  O. ,  J.  De Jonge ,  A.  Nomden ,  D.  Hoekstra , and  W.  Baron . 
 2009 .  Lovastatin induces the formation of abnormal myelin-
like membrane sheets in primary oligodendrocytes.  Glia .  57 : 
 402 – 413 . 
 147 .  Gaist ,  D. ,  U.  Jeppesen ,  M.  Andersen ,  L. A.  Garcia Rodriguez ,  J. 
 Hallas , and  S. H.  Sindrup .  2002 .  Statins and risk of polyneuropa-
thy: a case-control study.  Neurology .  58 :  1333 – 1337 . 
 148 .  Law ,  M. , and  A. R.  Rudnicka .  2006 .  Statin safety: a systematic re-
view.  Am. J. Cardiol.  97 :  52C – 60C . 
 149 .  Brown ,  W. V.  2008 .  Safety of statins.  Curr. Opin. Lipidol.  19 : 
 558 – 562 . 
 150 .  Verhave ,  P. S. ,  R. A.  Vanwersch ,  H. P.  van Helden ,  A. B.  Smit , and 
 I. H.  Philippens .  2009 .  Two new test methods to quantify motor 
defi cits in a marmoset model for Parkinson’s disease.  Behav. Brain 
Res.  200 :  214 – 219 . 
 151 .  Jurevics ,  H. A. , and  P.  Morell .  1994 .  Sources of cholesterol for 
kidney and nerve during development.  J. Lipid Res.  35 :  112 – 120 . 
 152 .  Morell ,  P. , and  H.  Jurevics .  1996 .  Origin of cholesterol in myelin. 
 Neurochem. Res.  21 :  463 – 470 . 
 153 .  Kelley ,  R. I.  2000 .  Inborn errors of cholesterol biosynthesis.  Adv. 
Pediatr.  47 :  1 – 53 . 
 154 .  Ullrich ,  K. ,  H. G.  Koch ,  D.  Meschede ,  U.  Flotmann , and  U. 
 Seedorf .  1996 .  Smith-Lemli-Opitz syndrome: treatment with cho-
lesterol and bile acids.  Neuropediatrics .  27 :  111 – 112 . 
 155 .  Arun ,  P. ,  C. N.  Madhavarao ,  J. R.  Moffett ,  K.  Hamilton ,  N. E. 
 Grunberg ,  P. S.  Ariyannur ,  W. A.  Gahl ,  Y.  Anikster ,  S.  Mog ,  W. C. 
 Hallows ,  et al .  2010 .  Metabolic acetate therapy improves pheno-
type in the tremor rat model of Canavan disease.  J. Inherit. Metab. 
Dis.  33 :  195 – 210 . 
 156 .  Das ,  A. K. ,  R. D.  Holmes ,  G. N.  Wilson , and  A. K.  Hajra .  1992 . 
 Dietary ether lipid incorporation into tissue plasmalogens of hu-
mans and rodents.  Lipids .  27 :  401 – 405 . 
 157 .  Saito ,  K. ,  V.  Dubreuil ,  Y.  Arai ,  M.  Wilsch-Brauninger ,  D.  Schwudke , 
 G.  Saher ,  T.  Miyata ,  G.  Breier ,  C.  Thiele ,  A.  Shevchenko ,  et al . 
 2009 .  Ablation of cholesterol biosynthesis in neural stem cells in-
creases their VEGF expression and angiogenesis but causes neu-
ron apoptosis.  Proc. Natl. Acad. Sci. USA .  106 :  8350 – 8355 . 
 158 .  Karasinska ,  J. M. ,  F.  Rinninger ,  D.  Lutjohann ,  P.  Ruddle ,  S. 
 Franciosi ,  J. K.  Kruit ,  R. R.  Singaraja ,  V.  Hirsch-Reinshagen ,  J.  Fan , 
 L. R.  Brunham ,  et al .  2009 .  Specifi c loss of brain ABCA1 increases 
brain cholesterol uptake and infl uences neuronal structure and 
function.  J. Neurosci.  29 :  3579 – 3589 . 
 159 .  Spencer ,  B. J. , and  I. M.  Verma .  2007 .  Targeted delivery of pro-
teins across the blood-brain barrier.  Proc. Natl. Acad. Sci. USA .  104 : 
 7594 – 7599 . 
 160 .  Garbay ,  B. ,  F.  Boiron-Sargueil ,  M.  Shy ,  T.  Chbihi ,  H.  Jiang ,  J. 
 Kamholz , and  C.  Cassagne .  1998 .  Regulation of oleoyl-CoA syn-
thesis in the peripheral nervous system: demonstration of a link 
with myelin synthesis.  J. Neurochem.  71 :  1719 – 1726 . 
 161 .  Yao ,  J. K. ,  R. T.  Holman ,  M. F.  Lubozynski , and  P. J.  Dyck .  1980 . 
 Changes in fatty acid composition of peripheral nerve mye-
lin in essential fatty acid defi ciency.  Arch. Biochem. Biophys.  204 : 
 175 – 180 . 
 162 .  Bourre ,  J. M. ,  A.  Youyou ,  G.  Durand , and  G.  Pascal .  1987 .  Slow 
recovery of the fatty acid composition of sciatic nerve in rats fed a 
diet initially low in n-3 fatty acids.  Lipids .  22 :  535 – 538 . 
 163 .  Retra ,  K. ,  O. B.  Bleijerveld ,  R. A.  van Gestel ,  A. G.  Tielens ,  J. J. 
 van Hellemond , and  J. F.  Brouwers .  2008 .  A simple and universal 
method for the separation and identifi cation of phospholipid mo-
lecular species.  Rapid Commun. Mass Spectrom.  22 :  1853 – 1862 . 
 164 .  Dod ,  B. J. , and  G. M.  Gray .  1968 .  The lipid composition of rat-liver 
plasma membranes.  Biochim. Biophys. Acta .  150 :  397 – 404 . 
 165 .  Ray ,  T. K. ,  V. P.  Skipski ,  M.  Barclay ,  E.  Essner , and  F. M.  Archibald . 
 1969 .  Lipid composition of rat liver plasma membranes.  J. Biol. 
Chem.  244 :  5528 – 5536 . 
 166 .  Lorincz ,  M. T. ,  S.  Rainier ,  D.  Thomas , and  J. K.  Fink .  2005 .  Cere-
brotendinous xanthomatosis: possible higher prevalence than 
previously recognized.  Arch. Neurol.  62 :  1459 – 1463 . 
 167 .  Brunham ,  L. R. ,  R. R.  Singaraja , and  M. R.  Hayden .  2006 .  Vari-
ations on a gene: rare and common variants in ABCA1 and their 
impact on HDL cholesterol levels and atherosclerosis.  Annu. Rev. 
Nutr.  26 :  105 – 129 . 
 168 .  Heim ,  P. ,  M.  Claussen ,  B.  Hoffmann ,  E.  Conzelmann ,  J.  Gartner , 
 K.  Harzer ,  D. H.  Hunneman ,  W.  Kohler ,  G.  Kurlemann , and  A. 
 Kohlschutter .  1997 .  Leukodystrophy incidence in Germany.  Am. 
J. Med. Genet.  71 :  475 – 478 . 
 169 .  Gustavson ,  K. H. , and  B.  Hagberg .  1971 .  The incidence and ge-
netics of metachromatic leucodystrophy in northern Sweden.  Acta 
Paediatr. Scand.  60 :  585 – 590 . 
 170 .  Schuchman ,  E. H.  2007 .  The pathogenesis and treatment of 
acid sphingomyelinase-defi cient Niemann-Pick disease.  J. Inherit. 
Metab. Dis.  30 :  654 – 663 . 
 171 .  Jagell ,  S. ,  K. H.  Gustavson , and  G.  Holmgren .  1981 .  Sjogren-
Larsson syndrome in Sweden. A clinical, genetic and epidemio-
logical study.  Clin. Genet.  19 :  233 – 256 . 
 172 .  Lazarow ,  P. B. , and  H. W.  Moser .  1989 . Disorders of peroxisome 
biogenesis.  In The Metabolic Basis of Inherited Disease. C. R. 
Scriver, A. L. Beaudet, W. S. Sly, and D. Valle, editors. McGraw-
Hill, New York. 1479–1509. 
 173 .  Berger ,  J. , and  J.  Gartner .  2006 .  X-linked adrenoleukodystrophy: 
clinical, biochemical and pathogenetic aspects.  Biochim. Biophys. 
Acta .  1763 :  1721 – 1732 . 
 174 .  Feigenbaum ,  A. ,  R.  Moore ,  J.  Clarke ,  S.  Hewson ,  D.  Chitayat ,  P. N. 
 Ray , and  T. L.  Stockley .  2004 .  Canavan disease: carrier-frequency 
determination in the Ashkenazi Jewish population and develop-
ment of a novel molecular diagnostic assay.  Am. J. Med. Genet. A. 
 124A :  142 – 147 . 
 175 .  Brun ,  N. ,  Y.  Robitaille ,  A.  Grignon ,  B. H.  Robinson ,  G. A.  Mitchell , 
and  M.  Lambert .  1999 .  Pyruvate carboxylase defi ciency: prenatal 
onset of ischemia-like brain lesions in two sibs with the acute neo-
natal form.  Am. J. Med. Genet.  84 :  94 – 101 . 
 at Vrije Universiteit, Library, Dept. of Electronic Resources, on February 12, 2013
w
w
w
.jlr.org
D
ow
nloaded from
 
